RESEARCH POSTER PRESENTATIONS SESSION V: Wednesday, 7 November 2012

Click on the topic below to view posters

SESSION V – WEDNESDAY, 7 NOVEMBER
SET-UP: Wednesday, 7 November, 8:30-8:45
POSTER DISPLAY HOURS: Wednesday, 7 November, 8:45-14:45
POSTER AUTHOR DISCUSSION HOUR: Wednesday, 7 November, 12:45-13:45
DISMANTLE: Wednesday, 7 November, 14:45

HEALTH SERVICES – Clinical Outcomes Studies

PHS1

THE EFFECT OF POSITIONING AND PNF-EXERCISE TO POSTOPERATIVE BLEEDING AFTER HIP REPLACEMENT

 

Gombos G1, Steinhausz V1, Bajsz V1, Sió E1, Turcsanyi K1, Molics B2, Boncz I2, Schmidt B1
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary

PHS2

POPULATION RISK STRATIFICATION: BASED ON THE COST OF CARE IN PATIENTS WITH CHRONIC DISEASES

 

Sicras-Mainar A, Llopart J, Ibañez J
Badalona Serveis Assistencials, Badalona, Barcelona, Spain

PHS3

ASSESSING THE SURVIVAL RATES AND ECONOMIC BURDEN OF PROSTATE CANCER IN THE U.S. VETERAN POPULATION

 

Baser O1, Xie L2, Huang A3, Li L3, Fritschel EK3, Wang L3
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research, Ann Arbor, MI, USA, 3STATinMED Research, Dallas, TX, USA

PHS4

WITHDRAWN

 

 

PHS5

ASSESSING THE CLINICAL AND ECONOMIC BURDEN OF U.S. VETERAN ANKYLOSING SPONDYLITIS PATIENTS

 

Xie L1, Baser O2, Huang A3, Li L3, Fritschel EK3, Wang L3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 3STATinMED Research, Dallas, TX, USA

PHS6

DIAGNOSIS RATES FOR ALZHEIMER'S DISEASE IN TAIWAN IN 2005 BY AGE USING NATIONAL HEALTH INSURANCE CLAIMS DATA

 

Hung YN1, Kadziola Z2, Fuh JL3, Hwang JP4, Lin C5, Brnabic A6, Belger MA7, Montgomery W8
1National Yang-Ming University, Taipei, Taiwan, 2Eli Lilly and Company, Vienna, Austria, 3Taipei Veterans General Hospital, Taipei, Taiwan, 4Veterand General Hospital, Taipei, Taiwan, Taipei, Taiwan, 5Eli Lilly and Company, Taipei, Taiwan, 6OptumInsight Asia Pacific, Lilyfield , New South Wales, Australia, 7Eli Lilly and Company, Windlesham, Surrey, UK, 8Eli Lilly and Company, West Ryde, NSW, Australia

PHS7

PREVALENCE AND COST OF ILLNESS OF SPECIFIC CONDITIONS IN A COMMERCIALLY INSURED UNITED STATES POPULATION

 

Eisenberg D1, Sanchez RJ2, White TJ3
1HealthCore, Inc., Wilmington, DE, USA, 2Pfizer, Inc., New York, NY, USA, 3WellPoint, Inc., Costa Mesa, CA, USA

PHS8

USE OF HEALTH CARE ADMINISTRATIVE DATABASES TO ESTIMATE INCIDENCE OF FOOT COMPLICATIONS IN DIABETES PATIENTS

 

Scalone L1, Furneri G2, Ciampichini R2, Cortesi PA1, Fornari C1, Madotto F1, Chiodini V1, Mantovani LG3, Cesana G1
1University of Milano - Bicocca, Monza, Italy, 2Charta Foundation, Milan, Italy, 3Federico II University of Naples, Naples , Italy

PHS9

REGIONAL AND AGE DISTRIBUTION EVALUATION OF THE OUTPATIENT CARE PHYSIOTHERAPY SERVICES FOR HIGH INCIDENCE TRAUMATIC INJURIES

 

Molics B1, Sebestyen A2, Kránicz J1, Schmidt B3, Nőt L1, Vámhidy L1, Cs. Horváth Z4, Varga S1, Gresz M5, Boncz I1
1University of Pécs, Pécs, Hungary, 2Baranya County Health Insurance Fund, Pécs, Hungary, 3University of Pécs, Zalaegerszeg, Hungary, 4National Institute for Quality- and Organizational Development in Healthcare and Medicines, Pécs, Hungary, 5National Institute for Quality- and Organizational Development in Healthcare and Medicines, Budapest, Hungary

PHS10

HBA1C TESTING FREQUENCY IN PRIMARY CARE DIABETES PATIENTS IN GERMANY AND IN THE UNITED KINGDOM

 

Kostev K, Grunow S, Rockel T
IMS Health, Frankfurt am Main, Germany

PHS11

RELATIONSHIP BETWEEN PHYSICAL FUNCTION AND MUSCLE STRENGTH IN THE UNITED STATES ELDERLY POPULATION

 

Zhao Y, Zhu Y, Cui Z, Chen L
Eli Lilly and Company, Indianapolis, IN, USA

PHS12

META-ANALYSIS OF PARKINSON'S DISEASE RISK WITH HYPERTENSION, SERUM TOTAL CHOLESTEROL, AND DIABETES MELLITUS

 

Mounika P1, Venkat A2, Chaitanya P3, Dev K4
1Vasavi college of pharmacy, Thadipalligudem, Andhra Pradesh, India, 2Long Island University, Brooklyn, NY, USA, 3Lalitha College of Pharmacy, Secundrabad, Andhra Pradesh, India, 4Sri Krupa Institute of Pharmaceutical Sciences, Siddipet, Andhra Pradesh, India

HEALTH SERVICES – Cost Studies

PHS13

COSTS ANALYSIS OF A MOBILE PHONE TELEMONITORING SYSTEM FOR GLYCAEMIC CONTROL IN PATIENTS WITH DIABETES MELLITUS (DM) IN SPAIN: PRELIMINARY RESULTS

 

Carral Sanlaureano F1, Sanchez P2, Lizan L2
1Hospital Universitario de Puerto Real, San Fernando, Cadiz, Spain, 2Outcomes 10, Castellon, Castellon, Spain

PHS14

CLINICAL AND ECONOMIC ANALYSIS OF “MOLICARE® PREMIUM EXTRA SOFT” DIAPERS EFFICIENT APPLICATION FOR DERMATITIS AND PRESSURE ULCERS' PROPHYLAXIS FOR IMMOBILE URINARY-INCONTINENT PATIENTS

 

Vorobiev P1, Krasnova L1, Shustov A1, Smola H2, Farafonova A3
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Paul Hartmann AG, Heidenheim, Germany, 3Marketing manager in Russia and Kazakhstan, Moscow, Russia

PHS15

RECOMMENDATION FOR ROTAVIRUS VACCINATION AND HERD EFFECT: ANALYZING COST DATA FROM A GERMAN STATUTORY HEALTH INSURANCE

 

Karmann A, Lukas D, Jurack A
Technische Universität Dresden, Dresden, Saxony, Germany

PHS16

RELATIONSHIP OF POLYMEDICATION IN CONTROLLING BLOOD PRESSURE: COMPLIANCE, PERSISTENCE, COSTS AND INCIDENCE OF NEW CARDIOVASCULAR EVENTS

 

Sicras-Mainar A1, Muñoz G2, Font B3, Majos N2, Navarro R4, Ibañez J1
1Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 2Novartis Farmaceutica, Barcelona, Barcelona, Spain, 3Novartis Farmaceutica, Barcelona, Spain, 4Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

PHS17

WITHDRAWN

 

Garin O1, Galante M2, Hollmann M3, Sicuri E2, Cots F4, Garcia-Altés A5, Ferrer M6, Dominguez À2, Castilla J7, Alonso J6
1IMIM (Institut de Recerca Hospital del Mar), Barcelona, Spain, 2CIBERESP, Barcelona, Spain, 3Pompeu Fabra University, Barcelona, Spain, 4Parc de Salut Mar, Barcelona, Spain, 5Catalan Agency for Health Information, Assessment and Quality (CAHIAQ), Barcelona, Spain, 6IMIM-Research Institute Hospital del Mar, Barcelona, Spain, 7Instituto de Salud Pública de Navarra, Pamplona, Spain

PHS18

ECONOMIC BURDEN OF ATOPIC DERMATITIS FROM A UNITED STATES PAYER PERSPECTIVE

 

Joish VN1, Sullivan SD2, Hartisch C3, Kamalakar R4, Eichenfield LF5
1Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 2School of Pharmacy, University of Washington, Seattle , WA, USA, 3Bayer HealthCare Consumer Care, Berlin, Germany, 4Bayer Pharmaceuticals, Wayne, NJ, USA, 5University of California San Diego, San Diego, CA, USA

PHS19

MACRO-COSTING ANALYSIS OF HOSPITAL STAY IN HEART FAILURE PATIENTS IN TURKISH SETTING

 

Ergene O1, Kocabas U1, Akyildiz I1, Eren NK1, Tan M2, Ozdemir O3
1Atatürk Training and Research Hospital, Izmir, Turkey, 2Servier Ilac ve Arastirma A.S., Istanbul, Turkey, 3Yorum Consulting Co. Ltd., Istanbul, Turkey

PHS20

COST ASSOCIATED TO THE MANAGEMENT OF INAPPROPRIATE SHOCKS IN PATIENTS WITH AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR – CARDINA STUDY

 

Pereferrer D1, Sicras-Mainar A2, Villuengas R1, Alcaide O1, Lloreda M1, Labata C1, Navarro R1, Bayes A1, Martí B3
1Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain, 2Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 3Medtronic, Madrid, Madrid, Spain

PHS21

OUT-OF-POCKET FINANCIAL BURDEN IN ATRIAL FIBRILLATION AND POTENTIAL IMPACT ON CARE: COMPARISON ACROSS FIVE EUROPEAN COUNTRIES USING THE EUROPEAN PATIENT SURVEY IN ATRIAL FIBRILLATION (EUPS-AF)

 

Mittendorf T1, Zamorano JL2, Bakhai A3, Berto P4, Leach N5, Sandberg A6, Oberdiek A7, Greiner W8
1Herescon GmbH, Hannover, Germany, 2Hospital Ramón y Cajal, Madrid, Spain, 3Barnet and Chase Farm Hospitals NHS Trust, London, London, UK, 4University of Padova and Analytica Laser, Verona, Italy, 5Oxford PharmaGenesis, Oxford, Oxford, UK, 6Daiichi Sankyo Europe GmbH, Munich, Germany, 7Daiichi Sankyo Europe, Munich, Germany, 8Universität Bielefeld, Bielefeld, Germany

PHS22

BURDEN OF INVASIVE PNEUMOCOCCAL DISEASES IN OLDER ADULTS IN THE NEW EU COUNTRIES OF THE CENTRAL EUROPE

 

Tichopad A1, Roberts CS2, Skoczynska A3, Hryniewitz W3, Gembula I4, Hajek P5, Krizova P6, Motlova J7, Avdicova M8
1CEEOR s.r.o., Prague, Czech Republic, 2Pfizer, New York, NY, USA, 3National Medicines Institute, Warsaw, Poland, 4CEEOR s.r.o., Prague, Slovak Republic, 5Pfizer s r.o., Prague, Czech Republic, 6Centre of Epidemiology and Microbiology, Prague, Czech Republic, 7National Reference Laboratory for Streptococci and Enterococci, Prague, Czech Republic, 8Regional Public Health Office, Department of Epidemiology, Banska Bystrica, Slovak Republic

PHS23

DIRECT MEDICAL COSTS ASSOCIATED WITH STROKE IN NON-VALVULAR ATRIAL FIBRILLATION IN INDIA

 

Marfatia S1, Sangole N2, Munshi S1, Tiwari A1, Patel M1, Suvarna V3, Bhure S3, Monz BU4
1pharmEDGE, Syosset, NY, USA, 2Boehringer Ingelheim, Mumbai, India, 3Boehringer Ingelheim, Mumbai, Mumbai, India, 4Boehringer Ingelheim GmbH, Ingelheim, Germany

PHS24

COST OF TRAFFIC ACCIDENTS RELATED TO LOW VISIBILITY CONDITIONS: A COST OF ILLNESS STUDY

 

Fekete J1, Várady G2, Vattay P1, Boncz I2
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary

PHS25

DIRECT MEDICAL COSTS OF MEDICAL CARE OF GASTROINTESTINAL BLEEDING IN MEXICO

 

Contreras I1, Moreno-Madrigal LG2, Cruz-Soriano I3
1Instituto Mexicano del Seguro Social, México City, Mexico, 2Hospital General de Zona No. 1-A Instituto Mexicano del Seguro Social, Mexico, Mexico, 3Hospital General de Zona No. 1-A Instituto Mexicano del Seguro Social, Mexico, Mexico, Mexico

PHS26

ECONOMIC BURDEN OF SEASONAL INFLUENZA B IN FRANCE DURING WINTER 2010-2011

 

Silva ML1, Perrier L2, Spath HM3, Mosnier A4, Cohen JM4
1Research Group in Health Economics (GATE, UMR 5824, CNRS); University Lyon 1; University Lyon 2, Lyon, France, 2Cancer Centre Léon Bérard, Lyon, France, 3ISPB - Faculte de Pharmacie - Universite Lyon 1, Lyon, France, 4Regional Group for the Surveillance of Influenza - GROG, Open Rome, Paris, Paris, France

PHS27

EVALUATION OF THE CLINICAL AND ECONOMIC BURDEN OF THE HUMAN IMMUNODEFICIENCY VIRUS IN U.S. VETERAN PATIENTS

 

Wang L1, Baser O2, Huang A1, Li L1, Fritschel EK1, Xie L3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 3STATinMED Research, Ann Arbor, MI, USA

PHS28

THE COST OF MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION : AN OBSERVATIONAL STUDY IN UK NHS PRIMARY CARE

 

Kassianos G1, Fuat A2, Arden CD3, Hogan S4, Baldock L5
1The Birch Hill Medical Centre, Bracknell, Berkshire, UK, 2Carmel Medical Practice (Darlington) and University of Durham, Durham, UK, 3Park Surgery, Eastleigh, Hampshire, UK, 4Sanofi, Guildford, Surrey, UK, 5pH Associates Ltd, Marlow, Buckinghamshire, UK

PHS29

COST OF TREATING PATIENTS WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYDROME IN THE SOTIRIA CHEST HOSPITAL IN GREECE

 

Prapa P1, Geitona M2, Gourgoulianis K3
1Sotiria Chest Hospital, Athens, Greece, 2University of Peloponnese, Korinth, Greece, Greece, 3University of Thessaly, Larissa, Greece

PHS30

HEALTH CARE COSTS IN PSORIATIC ARTHRITIS (PSA) PATIENTS NEWLY INITIATED ON A BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUG (DMARDS) OR METHOTREXATE (MTX)

 

Zhang F1, Hiscock R2, Curtis J3
1Celgene Corporation, Summit, NJ, USA, 2Analysis Group, Inc., Montreal, QC, Canada, 3University of Alabama at Birmingham, Birmingham, AL, USA

PHS31

DETERMINATION OF THE ANNUAL HEALTH INSURANCE COST OF OUTPATIENT CARE PHYSIOTHERAPY SERVICES FOR MUSCULOSKELETAL AND CONNECTIVE TISSUE DISEASES

 

Molics B1, Turcsanyi K2, Sebestyén A3, Kránicz J1, Schmidt B2, Oláh A1, Nőt L1, Gresz M4, Cs. Horváth Z5, Boncz I1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3South-Trasdanubian Regional Health Insurance Fund Administration, Pécs, Hungary, 4National Institute for Quality- and Organizational Development in Healthcare and Medicines, Budapest, Hungary, 5National Institute for Quality- and Organizational Development in Healthcare and Medicines, Pécs, Hungary

PHS32

DETERMINATION OF THE ANNUAL HEALTH INSURANCE COST OF OUTPATIENT CARE PHYSIOTHERAPY SERVICES FOR TRAUMA PATIENTS

 

Molics B1, Sebestyén A2, Kránicz J1, Schmidt B3, Nőt L1, Vámhidy L1, Oláh A1, Varga S1, Cs. Horváth Z4, Boncz I1
1University of Pécs, Pécs, Hungary, 2South-Trasdanubian Regional Health Insurance Fund Administration, Pécs, Hungary, 3University of Pécs, Zalaegerszeg, Hungary, 4National Institute for Quality- and Organizational Development in Healthcare and Medicines, Pécs, Hungary

PHS33

COST ANALYSIS OF DIALYSIS PRACTICE IN TURKEY

 

Tatar M1, Ergin Oguzhan G2, Kockaya G2
1Hacettepe University, Ankara, Turkey, 2Health Economics and Policy Association, Ankara, Turkey

PHS34

THE COST OF MANAGEMENT OF COMMON CARDIOVASCULAR DISEASES IS HIGHER ON WEEKENDS AS COMPARED TO WEEKDAYS

 

Oguz A1, Ozdemir O2
1Goztepe Training and Research Hospital, Istanbul, Turkey, 2Yorum Consulting Co. Ltd., Istanbul, Turkey

PHS35

THE DISTRIBUTION OF OUTPATIENT PHYSIOTHERAPY SERVICES IN HUNGARY

 

Molics B1, Gombos G2, Ágoston I1, Kránicz J1, Schmidt B2, Nőt L1, Cs. Horváth Z3, Gresz M4, Boncz I1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3National Institute for Quality- and Organizational Development in Healthcare and Medicines, Pécs, Hungary, 4National Institute for Quality- and Organizational Development in Healthcare and Medicines, Budapest, Hungary

PHS36

COST DRIVERS OF HOUSEHOLD TREATMENT OF PRESUMPTIVE MALARIA IN HOME-BASED MANAGEMENT OF MALARIA IN EJISU-JUABEN MUNICIPALITY

 

Agyei-Baffour P1, Asante BO2
1Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, 2ZoomLion Ghana Limited, Accra, Ghana

PHS37

COST MINIMIZATION ANALYSIS IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA IN UKRAINE

 

Vadziuk I, Markiv I, Klishch I
Ivan Horbachevsky Ternopil State Medical University, Ternopil, Ukraine

PHS38

COST-EFFECTIVENESS ANALYSIS OF A HELPLINE FOR SUICIDE PREVENTION

 

Pil L1, Annemans L2, Pauwels K3, Muijzers E3, Portzky G3
1Ghent University, Gent, Belgium, 2Ghent University & Brussels University, Ghent, Belgium, 3Flemish Centre For Suicide Prevention, Brussels, Belgium

 

PHS39

COST-EFFECTIVENESS OF A NURSE-LED INTEGRATED CHRONIC CARE APPROACH VERSUS USUAL CARE IN PATIENTS WITH ATRIAL FIBRILLATION

 

Hendriks JM1, Tomini F2, van Asselt AD2
1Maastricht University Medical Centre, Maastricht, Limburg, The Netherlands, 2Maastricht University Clinical Center, Maastricht, Limburg, The Netherlands

PHS40

AN EXAMPLE OF IRRATIONAL DECISION MAKING IN THE ELDERLY: WHY ARE PHARMACOLOGICAL THERAPIES PREFERENTIALLY REIMBURSED OVER NON-PHARMACOLOGICAL THERAPIES FOR INSOMNIA?

 

Singh D
University de Montreal, Montreal, QC, Canada

PHS41

COST EFFECTIVENESS ANALYSIS OF TWO HIV COUNSELING AND TESTING STRATEGIES IN KAYUNGA DISTRICT (UGANDA)

 

Muhumuza C1, Mohammed L2, Baine S1, Mupere E1, Mukose A1
1Makerere University, KAMPALA, Uganda, 2Infectious Diseases Institute, KAMPALA, Uganda

PHS42

COST-EFFECTIVENESS OF INFANT VACCINATION WITH 10 AND 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE RUSSIAN FEDERATION

 

Rudakova AV1, Sidorenko S1, Kharit SM1, Uskov A1, Lobzin YV1, Shchurov DG2, Topachevskyi O3
1Scientific Research Institute of 'Children Infections' SMBA, Saint-Petersburg, Russia, 2GlaxoSmithKline Trading, Moscow, Russia, 3GlaxoSmithKline Vaccines, Wavre, Belgium

PHS43

COST-EFFECTIVENESS ANALYSIS OF THERAPEUTIC DRUG MONITORING IN PEDIATRIC PATIENTS DIAGNOSED WITH STRUCTURAL-METABOLIC EPILEPSY

 

Salih MRM1, Bahari MB2, Shafie AA3, Ahmad Hassali MA4, Al-lela OQB5, Abd AY1, Ganesan V6
1College of Pharmacy, Al-Rashed University, Baghdad, Iraq, 2Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia, 3Universiti Sains Malaysia, Penang, Malaysia, 4Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia, 5Department of Pharmacy Practice, Kulliyyah of Pharmacy, International Islamic University Malaysia, Pahang , Malaysia, 6Department of Paediatrics, Hospital Pulau Pinang, Penang, Malaysia

PHS44

ECONOMIC EVALUATION OF UNIVERSAL HEPATITIS B VACCINATION STRATEGY IN JAPAN

 

Hirao T1, Sato T2, Sugimori H3, Suka M4, Yoda T1, Yoshioka A1, Akazawa M5, Igarashi A6, Kobayashi M7, Ikeda S8
1Kagawa University, Miki, Kagawa, Japan, 2Kitasato University, Sgamihara, Kanagawa, Japan, 3Daito Bunka University, Higashi Matsuyama, Saitama, Japan, 4Jikei University, Minato-ku, Tokyo, Japan, 5Meiji Pharmaceutical University, Kiyose, Tokyo, Japan, 6Tokyo Univ. Faculty of Pharmacy, Tokyo, Japan, 7Chiba University, Chiba, Japan, 8International University of Health and Welfare, Otawara City, Tochigi, Japan

PHS45

COST EFFECTIVENESS ANALYSIS OF A SPECIALIST SERVICE AND ADRENALINE INJECTORS IN ANAPHYLAXIS

 

Armstrong N, van Mastrigt G, Wolff R, Kleijnen J
Kleijnen Systematic Reviews Ltd., York, UK

PHS46

COST-EFFECTIVENESS OF A SECONDARY PREVENTION PROGRAM IN PATIENTS WITH MYOCARDIAL INFARCTION: RESULTS FROM A RANDOMISED CONTROLLED TRIAL (PROACTIVE HEART)

 

Turkstra E1, Hawkes AL2, Oldenburg BF3, Scuffham PA1
1Griffith University, Meadowbrook, Queensland, Australia, 2Cancer Council Queensland, Fortitude Valley, Queensland, Australia, 3Monash University, Melbourne, Victoria, Australia

PHS47

COST-UTILITY ANALYSIS OF ROTIGOTINE IN RESTLESS LEGS SYNDROME FROM THE NHS SCOTLAND PERSPECTIVE

 

Benhaddi H1, Lundie G2
1UCB Pharma, Brussels, Belgium, 2UBC Pharma, Slough, UK

PHS48

COST-EFFECTIVENESS ANALYSIS OF TOLVAPTAN FOR HYPONATREAMIA IN SOUTH KOREA

 

Kang HJ1, Choi J1, Lee MY2, Lee EK1
1Sungkyunkwan University, Suwon, South Korea, 2Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea

PHS49

COST OF HYPOGLYCAEMIA IN PATIENTS WITH DIABETES IN POLAND

 

Widz K1, Czech M2, Hermanowski T3
1Medical University of Warsaw, Warsaw, Poland, 2Novo Nordisk Pharma Sp z.o.o., Warsaw, Poland, 3Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland

PHS50

HEALTH CARE RESOURCE USE AND COST IN ALZHEIMER'S DISEASE IN THREE EUROPEAN COUNTRIES – BASELINE FINDINGS OF THE GERAS STUDY

 

Reed C1, Argimon J2, Belger MA1, Bruno G3, Dodel R4, Happich M5, Haro JM6, Jones RW7, Vellas B8, Wimo A9
1Eli Lilly and Company, Windlesham, Surrey, UK, 2Servei Catala de la Salut, Barcelona, Spain, 3University of Rome, Rome, Italy, 4Philipps University, Marburg, Hessen, Germany, 5Eli Lilly and Company, Bad Homburg, Germany, 6Parc Santari Sant Joan de Déu, CIBERSAM, Barcelona, Spain, 7The Rice Centre, Royal United Hospital, Bath, UK, 8Toulouse University Hospital, Toulouse, France, 9Karolinska Institutet, Stockholm, Sweden

PHS51

HOSPITAL STAYS OF MULTIPLE SCLEROSIS PATIENTS IN GERMANY – REASONS, FREQUENCIES, DURATION AND IMPACT ON DRUG THERAPY

 

Seiffert A1, Dippel FW2, Sommer G2, Holz B3, Trottmann M4
1Gesundheitsforen Leipzig GmbH, Leipzig, Germany, 2Sanofi Deutschland GmbH, Berlin, Germany, 3Genzyme GmbH, Neu Isenburg, Germany, 4Gesundheitsforen Leipzig GmbH, München, Germany

PHS52

ESTIMATING THE RESOURCES NEEDED TO IMPLEMENT A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAM THROUGH DISCRETE EVENT SIMULATION

 

Comas M1, Arrospide A2, Mendivil J3, Mar J2, Hernandez C3, Buron A1, Andreu M3, Castells X1
1IMIM (Institut de Recerca Hospital del Mar) Parc de Salut MAR; CIBER de Epidemiología y Salud Pública, Barcelona, Spain, 2Hospital Alto Deba, Mondragon, Spain, 3IMIM (Institut de Recerca Hospital del Mar) Parc de Salut MAR, Barcelona, Spain

PHS53

USE OF HEALTH CARE ADMINISTRATIVE DATABASES TO ESTIMATE THE BURDEN OF MULTIPLE SCLEROSIS: A POPULATION-BASED STUDY

 

Furneri G1, Ciampichini R1, Scalone L2, Cortesi PA2, Fornari C2, Madotto F2, Chiodini V2, Mantovani LG3, Cesana G2
1Charta Foundation, Milan, Italy, 2University of Milano - Bicocca, Monza, Italy, 3Federico II University of Naples, Naples , Italy

PHS54

USE OF HEALTH CARE ADMINISTRATIVE DATABASES TO ESTIMATE THE HEALTH CARE BURDEN OF BONE OR BONE MARROW METASTATIC DEASES IN BREAST CANCER PATIENTS: A POPULATION-BASED STUDY

 

Mantovani LG1, Scalone L2, Furneri G3, Ciampichini R3, Cortesi PA2, Fornari C2, Madotto F2, Chiodini V2, Cesana G2
1Federico II University of Naples, Naples , Italy, 2University of Milano - Bicocca, Monza, Italy, 3Charta Foundation, Milan, Italy

PHS55

INEQUALITIES AND AVOIDABLE COSTS OF IMAGING TEST IN THE DIAGNOSIS AND MONITORING OF PATIENTS WITH STROKE IN THE CANARY ISLANDS

 

Valcárcel-Nazco C1, Castilla-Rodríguez I2, Ramos-Goñi J1, Serrano-Aguilar P3
1FUNCIS, Santa Cruz de Tenerife, Canary Islands, Spain, 2Ciber de Epidemiología y Salud Pública (CIBERESP), Santa Cruz de Tenerife, Tenerife, Spain, 3Canary Islands Health Service, Santa Cruz de Tenerife, Canary Islands, Spain

HEALTH SERVICES – Patient-Reported Outcomes & Patient Preference Studies

PHS56

EVALUATION OF TELEMEDICINE PROGRAM (ITHACA): INNOVATION IN THE TREATMENT OF ARTERIAL HYPERTENSION INCREASING THE COMPLIANCE AND ADHERENCE

 

Sicras-Mainar A1, Ibañez J1, Frias X1, Bulto C1, Costa A2, Majos N2, Lahoz R2
1Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 2Novartis Farmaceutica, Barcelona, Spain

PHS57

COMPARING PREDICTORS OF SELF-REPORTED ADHERENCE TO MAMMOGRAPHY SCREENING GUIDELINES IN APPALACHIAN WOMEN WHO UTILIZE MOBILE AND STATIONARY FACILITIES

 

Vyas A, Madhavan S
West Virginia University School of Pharmacy, Morgantown, WV, USA

PHS58

CHANGE IN HEALTH-RELATED QUALITY OF LIFE AFTER OCCPATIONAL THERAPY IN COMMUNITY-DWELLING DEPENDENT ELDERLY: A RANDOMISED CONTROLED TRIAL

 

Noto S1, Uemura T2, Moriwaki K1
1Niigata University of Health and Welfare, Niigata, Japan, 2Kyorin University, Mitaka-shi, Japan

PHS59

DEMOGRAPHICS AND HEALTH-STATE UTILITIES OF IRISH PATIENTS WITH HEPATITIS C INFECTION; USE OF THE 5-LEVEL EQ-5D QUESTIONNAIRE

 

Kieran J1, Mushtaq H2, Bergin C2, Norris S2, Barry M3
1Trinity College Dublin, Dublin, Ireland, 2St James Hospital, Dublin, Ireland, 3St. James's Hospital, Dublin, Ireland, Ireland

PHS60

HEALTH-RELATED QUALITY OF LIFE IN HIV/HCV CO-INFECTED PATIENTS IN IRELAND

 

McGreal-Bellone A1, Cleary S1, Farrell G2, Bergin C2, Barry M3, Kieran J1
1Trinity College Dublin, Dublin, Ireland, 2St James Hospital, Dublin, Ireland, 3St. James's Hospital, Dublin, Ireland, Ireland

PHS61

PATIENT INVOLVEMENT IN TREATMENT DECISIONS AND ITS PERCEIVED IMPACT ON PATIENT OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A COMPARISON OF PHYSICIAN AND PATIENT PERSPECTIVES

 

Grinspan J1, Beusterien K1, Parker T2, Bell JA1, Kan H3, Dietrich CN1, Utset TO4, Narayanan S5
1Oxford Outcomes, Bethesda, MD, USA, 2Qessential Medical Market Research, Exeter, NH, USA, 3GlaxoSmithKline, Research Triangle Park, NC, USA, 4University of Chicago Department of Medicine, Chicago, IL, USA, 5Human Genome Sciences, Inc., Rockville, MD, USA

PHS62

ASSESSMENT OF PATIENT SATISFACTION WITH CHRONIC TREATMENT USING THE EUROPEAN PATIENT SURVEY IN ATRIAL FIBRILLATION (EUPS-AF)

 

Bakhai A1, Greiner W2, Mittendorf T3, Berto P4, Campbell D5, Sandberg A6, Oberdiek A7, Zamorano JL8
1Barnet and Chase Farm Hospitals NHS Trust, London, London, UK, 2Universität Bielefeld, Bielefeld, Germany, 3Herescon GmbH, Hannover, Germany, 4University of Padova and Analytica Laser, Verona, Italy, 5Oxford PharmaGenesis, Oxford, Oxford, UK, 6Daiichi Sankyo Europe GmbH, Munich, Germany, 7Daiichi Sankyo Europe, Munich, Germany, 8Hospital Ramón y Cajal, Madrid, Spain

PHS63

PATIENT PERCEPTION OF AN ORAL SYSTEMIC ANTI-CANCER THERAPY HOMECARE SERVICE

 

Kilby S
Surrey, West Sussex and Hampshire Cancer Network, Guilford, Surrey, UK

PHS64

SHARED DECISION MAKING IN SECONDARY CARE: RHEUMATOLOGIC PATIENT'S PERSPECTIVE

 

Battisti R1, Baumgratz TD1, Cuziol M1, Janini ACR1, Levy RA2, Abreu MM1
1Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil, 2Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil

PHS65

MAPPING THE DISEASE-SPECIFIC FACT-P TO THE PREFERENCE-BASED EQ-5D IN CASTRATION-RESISTANT PROSTATE CANCER

 

Ivanescu C1, Skaltsa K2, Holmstrom S3
1Quintiles, Hoofddorp, The Netherlands, 2Bioclever, Barcelona, Spain, 3Astellas Pharma Global Development, Leiderdorp, The Netherlands

PHS66

OUTCOMES AND DETERMINANTS OF CAREGIVER BURDEN AFTER FIRST-EVER STROKE: THE ERLANGEN STROKE PROJECT (ESPRO)

 

Schaller SU, Weingärtner M, Kriza C, Niederländer C, Wahlster P, Kolominsky-Rabas P
University of Erlangen-Nuremberg, Erlangen, Germany

PHS67

RASCH MODEL VALIDATION OF A PEER RELATIONS SCALE FOR PEOPLE TREATED FOR PSYCHOACTIVE SUBSTANCE USE DISORDER

 

Ciesla J1, Mazurek K2
1Northern Illinois University, DeKalb, IL, USA, 2University of Illinois, Champaign-Urbana, Champaign, IL, USA

PHS68

AN ASSESSMENT OF IMPAIRMENT OF PRODUCTIVITY AMONG SLE PATIENTS

 

Schneider M1, Strand V2, Nikaï E3, Wood R4, Smets E3, Lobosco S4
1Heinrich-Heine-University, Düsseldorf, Germany, 2Stanford University, Portola Valley, CA, USA, 3UCB Pharma, Brussels, Belgium, 4Adelphi Real World, Bollington, Cheshire, UK

PHS69

IMPACT ASSESSMENT OF MINNESOTA MODEL FOR ALCOHOL REHABILITATION IN HOSPITALIZED PATIENTS

 

Tóth Á1, Szikszay P2, Sipos E1, Boncz I1, Jeges S1
1University of Pécs, Pécs, Hungary, 2Szigetvár Hospital, Szigetvár, Hungary

PHS70

HEALTH RELATED QUALITY OF LIFE AS PREDICTOR OF DEATH AMONG PATIENTS WITH HEART FAILURE

 

Escobar A1, Bilbao A1, Gonzalez-Saenz de Tejada M2, Fernandez-Soto M3, Lafuente I4, Sanchez-Haya E3, Citores L1
1Basurto University Hospital (Osakidetza), Bilbao, Bizkaia, Spain, 2Basurto University Hospital (Osakidetza) - CIBER Epidemiologia y Salud Pública (CIBERESP), Bilbao, Bizkaia, Spain, 3Donostia University Hospital (Osakidetza), Donostia-San Sebastian, Gipuzkoa, Spain, 4Galdakao-Usansolo Hospital (Osakidetza), Galdakao, Bizkaia, Spain

PHS71

HEALTH RELATED QUALITY OF LIFE OF HIV PATIENTS AT A TERTIARY CARE HOSPITAL IN BANGALORE

 

Kishore G1, Praveenkumar Y1, nagaraju R R2, Meera NK1
1Visveswarapura Institute Of Pharmaceutical Sciences, Bangalore, India, 2SPMVV, tirupati, India

PHS72

QUALITY OF LIFE WITH TYPE2 DIABETES: TRANSLATION AND VALIDATION OF INDIAN VERSION OF MDQ

 

Pawar S1, Thakurdesai P2
1Karpagam University and Smt. Kashiabai Navale College of Pharmacy, Pune, India, 2Indus Biotech, Pune, India

PHS73

WILLINGNESS OF THE HEALTH CARE CONSUMERS TO PAY FOR HEALTH CARE SERVICES – RESULTS FROM A CONTINGNET VALUATION STUDY

 

Baji P1, Pavlova M1, Gulácsi L2, Groot W1
1Maastricht University, Maastricht, The Netherlands, 2Corvinus University of Budapest, Budapest, Hungary

HEALTH SERVICES – Health Care Use & Policy Studies

PHS74

DOES DISEASE ADVOCACY IMPACT PRIORITY SETTING: EVIDENCE FROM THE NEEDS AND PRIORITIES FOR COMPREHENSIVE LIVER CANCER CONTROL IN 12 COUNTRIES IN EUROPE AND ASIA-PACIFIC

 

Bridges JF1, Joy SM1, Blauvelt BM2
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2University of Massachusetts, Hadley, MA, USA

PHS75

ANALYSIS OF COSTS AND REIMBURSEMENT OF HOSPITAL TREATMENT OF VENOUS THROMBOEMBOLISM IN POLAND

 

Bochenek T1, Nizankowski R2
1Jagiellonian University, Collegium Medicum, Krakow, Poland, 2Jagiellonian University, Krakow, Poland

PHS76

AN INFUENZA VACCINATION POLICY BASED ON A PREVIOUS YEAR'S ILLNESS

 

Yamin D, Gavious A, Solnik E, Davidovitch N, Pliskin JS
Ben Gurion University of the Negev, Beer-Sheva, Israel

PHS77

CANCER NETWORK PHARMACISTS PERSPECTIVE OF THE FIRST YEAR OF THE CANCER DRUGS FUND

 

Kilby S
Surrey, West Sussex and Hampshire Cancer Network, Guilford, Surrey, UK

PHS78

IMPACT OF EDUCATIONAL INTERVENTION ON CASE MANAGEMENT OF ARI AT COMMUNITY PHARMACIES IN ISLAMABAD PAKISTAN

 

Hussain A1, Ibrahim MI2, Malik M3
1Hamdard university, Islamabad, Punjab, Pakistan, 2College of Pharmacy, Qatar University, doha, Qatar, 3University Sains Malaysia, hamdard university, Islamabad, Pakistan

PHS79

THE ANALYSIS OF THE FORMULARY COMMITTEES IN KAZAKHSTANI REGIONS

 

Pichkhadze G1, Satbayeva E1, Akanova A2
1Kazakh National Medical University named after S.D. Asfendiyarov, Almaty, Kazakhstan, 2Kazakh National Medical University named after S.D. Asfendiyarov, Almaty, Kazakstan, Kazakhstan

PHS80

CLINICAL PRACTICE GUIDELINE MAJOR DEPRESSIVE DISORDER FOR GENERAL PRACTITIONERS

 

Kongsuk T
PRASRIMAHABHODI PSYCHIATRIC HOSPITAL, UBON RATCHATHANEE, UBON RATCHATHANE, Thailand

PHS81

HEALTH CARE ORGANIZATIONS/SERVICES CLUSTERING: COMPARISON OF SEVERAL TECHNIQUES USING UK DATA

 

Millier A1, Mejri S2, Aballea S1, Toumi M3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, tunis, Tunisia, 3University Claude Bernard Lyon 1, Lyon, France

PHS82

WITHDRAWN

 

 

PHS83

POTENTIAL TIME SAVINGS WITH RITUXIMAB SUBCUTANEOUS (SC) INJECTION VERSUS RITUXIMAB INTRAVENOUS (IV) INFUSION: RESULTS FROM INTERVIEWS AT 13 EUROPEAN SITES AS PART OF A TIME AND MOTION STUDY (T&M)

 

De Cock E1, Carella AM2, Tao S3, Wiesner C4
1United BioSource Corporation, Barcelona, Spain, 2KRCSS AOU, San Martino, Italy, 3United BioSource Corporation, Dorval, QC, Canada, 4F. Hoffmann-La Roche Ltd., Basel, Switzerland

PHS84

ANALYZING PHARMACEUTICAL EXPENDITURE IN GREECE:UNWINDING ARIADNE'S CLUE

 

Siskou O1, Kaitelidou D2, Schneider M3, Kalogeropoulou M1, Tsavalias K1, Passaloglou S4, Kouli E1, Galanis P1, Kontozamanis V1, Liaropoulos L1
1National and Kapodistrian University of Athens, Athens, Greece, 2National and Kapodistrian University of Athens, Athnes, Greece, 3BASYS, Augsburg, Germany, 4Novartis Hellas, Metamorfosi Athens, Greece

PHS85

THE COST OF PUBLIC CANCER PREVENTION IN ALBERTA

 

Jacobs P1, Moffatt J2
1Institute of Health Economice, Edmonton, AB, Canada, 2Institute of Health Economics, Edmonton, AB, Canada

PHS86

A POPULATION-BASED STUDY OF THE RESOURCE UTILIZATION AND COSTS OF TREATING RESECTABLE NON-SMALL CELL LUNG CANCER

 

Mahar AL, Johnson A
Queen's University, Kingston, ON, Canada

PHS87

COST OF DIABETES IN INSULIN-TREATED PATIENTS IN BULGARIA

 

Doneva M1, Valov V2, Borissova AM3, Tankova T3, Savova A1, Manova M1, Petrova G4, Czech M5
1Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 2Novo Nordisk Pharma EAD, Sofia, Bulgaria, 3Medical University, Faculty of medicine, Sofia, Bulgaria, 4Medical University, Faculty of Pharmacy, Sofia, Bulgaria, 5Novo Nordisk Pharma Sp z.o.o., Warsaw, Poland

PHS88

PHARMACIST HOUSE CALLS IN HOME CARE IN JAPAN

 

Imai H1, Nakao H2, Nanami Y3, Onda M3
1National Institute of Public Health, Wako-shi, Saitama-ken, Japan, 2National Institute of Public Health, Wako-shi, Japan, 3Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan

PHS89

HOW CAN WE MEASURE THE IMPACT OF CLINICAL PHARMACY INTERVENTIONS? A RETROSPECTIVE DRUG COST ANALYSIS

 

Claus B1, Robays H1, Annemans L2
1Ghent University Hospital, Ghent, Belgium, 2Ghent University & Brussels University, Ghent, Belgium

PHS90

HOW DO PHARMACISTS ADVISE DIABETES PATIENT SELF-MANAGEMENT DURING THE HOLY MONTH OF RAMADAN?

 

Wilbur K, Al-Tawengi K, Remoden E
Qatar University, Doha, Qatar

PHS91

WITHDRAWN

 

 

PHS92

ALLOCATION OF RESEARCH FUNDING IN HEALTH CARE IN RELATION TO DISEASE BURDEN IN EUROPE

 

Winter Y, Oertel W, Dodel R
Philipps University, Marburg, Hessen, Germany

PHS93

HBA1C TEST UTILIZATION AMONG HOSPITALIZED PATIENTS WITH HYPERGLYCEMIA

 

Eby E, Gelwicks S, Marchlowska PA
Eli Lilly and Company, Indianapolis, IN, USA

PHS94

INVOLVEMENT OF CNS SPECIALISTS IN HEALTH CARE PROVISION FOR PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): NEW DATA FROM NORDBADEN, GERMANY, 2003 - 2009

 

Schlander M1, Schwarz O1, Banaschewski T2, Trott GE3, Viapiano M4, Bonauer N5, Scheller W6
1Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany, 2University of Heidelberg, Mannheim, Germany, 3University of Wuerzburg, Aschaffenburg, Germany, 4KV BaWue, Karlsruhe, Germany, 5KV Baden-Wuerttemberg, Karlsruhe, Germany, 6Verband der Ersatzkassen (vdek), Stuttgart, Germany

PHS95

THE SUICIDALITY IN THAI POPULATION: A NATIONAL SURVEY

 

Leejongpermpoon J
Department of Mental Health, UBON RATCHATHANEE, UBON RATCHATHANE, Thailand

PHS96

THE IMPACT OF THE IMPLEMENTATION OF NICE GUIDANCE ON VENOUS THROMBOEMBOLISM RISK ASSESSMENT AND PATIENT SAFETY ACROSS FOUR HOSPITALS IN ENGLAND

 

Bateman AG1, Sheaff R2, Child S1, Boiko O3, Ukoumunne O3, Gericke CA1
1Peninsula Medical School/National Institute for Health Research, Plymouth, Devon, UK, 2Plymouth University, Plymouth, Devon, UK, 3Peninsula Medical School/National Institute for Health Research, Exeter, Devon, UK

PHS97

AN OFF-THE-SHELF CATALOGUE OF QUALITY IMPROVEMENT INTERVENTIONS TO IMPLEMENT IN THE PREVENTION OF PRESSURE ULCERS FOR HOSPITAL SETTINGS

 

Padula WV1, Makic MBF2, Mishra MK3, Wald H4, Nair KV5, Campbell J4, Valuck R6
1University of Colorado Health Sciences Center, Denver, CO, USA, 2University of Colorado Hospital, Aurora, CO, USA, 3Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA, 4University of Colorado, Aurora, CO, USA, 5University of Colorado, Denver, Aurora, CO, USA, 6University of Colorado School of Pharmacy, Aurora, CO, USA

PHS98

CLINICAL CHARACTERISTICS, TREATMENT PATTERNS, AND RESOURCE UTILIZATION IN A REAL-WORLD EUROPEAN POPULATION WITH DIVERTICULITIS

 

Davis KL1, Mitra D2, Yen L3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI International, Research Triangle Park, NC, USA, 3Shire Development LLC, Wayne, PA, USA

SESSION V – WEDNESDAY, 7 NOVEMBER
SET-UP: Wednesday, 7 November, 8:30-8:45
POSTER DISPLAY HOURS: Wednesday, 7 November, 8:45-14:45
POSTER AUTHOR DISCUSSION HOUR: Wednesday, 7 November, 12:45-13:45
DISMANTLE: Wednesday, 7 November, 14:45

INDIVIDUAL’S HEALTH – Clinical Outcomes Studies

PIH1

SPONTANEOUS ADVERSE DRUG REACTIONS REPORTING FORMS OF 55 DIFFERENT COUNTRIES – EVALUATION, COMPARISON, AND QUALITY CHECK

 

Abdul Razack HI1, Sree V2
1Accenture Services Ltd., Bangalore, Bangalore, India, 2Chalapathi Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India

PIH2

DULOXETINE USE IN PREGNANCY: A PROSPECTIVE, COMPARATIVE STUDY OF EXPOSED INFANTS

 

Einarson A1, Koren G1, Einarson TR2
1The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada, 2University of Toronto, Toronto, ON, Canada

PIH3

DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF MENOPAUSAL WOMEN IN THE UNIVERSITY OF MICHIGAN WOMEN'S REGISTRY DATABASE

 

Xie L1, Lewis-Beck C1, Wang H1, Altinbas S2, Baser O3
1STATinMED Research, Ann Arbor, MI, USA, 2Etlik Zübeyde Haným Women's Health Teaching and Research Hospital, Ankara, Turkey, 3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA

PIH4

NETWORK META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS TO PREVENT VENOUS THROMBOEMBOLISM FOLLOWING ELECTIVE KNEE AND HIP REPLACEMENT SURGERY: WHY EXTEND THE NETWORK?

 

Dequen P1, Kelly S2, Abrams K1
1University of Leicester, Leicester, UK, 2Pfizer Limited, Surrey, UK

PIH5

PREVENTABLE DRUG-RELATED HOSPITAL VISITS AND ADMISSIONS ASSOCIATED WITH LABORATORY OR PHYSIOLOGIC ABNORMALITIES - A SYSTEMATIC-REVIEW

 

Wilbur K, Hazi H, El-Badawi A
Qatar University, Doha, Qatar

PIH6

UNINTENTIONAL EXPOSURES TO BUPRENORPHINE/NALOXONE TABLETS AND ORAL FILM AMONG CHILDREN LESS THAN SIX YEARS OLD

 

Lavonas EJ1, Severtson SG1, Murrelle EL2, Ruby J3, Bucher-Bartelson B1, Dart RC1
1Denver Health and Hospital Authority, Denver, CO, USA, 2Venebio, Richmond, VA, USA, 3Reckitt Benckiser Pharmaceuticals, Inc./NA, Richmond, VA, USA

INDIVIDUAL’S HEALTH – Cost Studies

PIH7

NET TAX REVENUE WITH A NATIONAL BASED ROTAVIRUS VACCINATION PROGRAM IN TURKEY

 

Kockaya G1, Atikeler K2, Tuna E3
1Health Economics and Policy Association, Ankara, Turkey, 2Ankara University, Ankara, Turkey, 3Hacettepe University, Ankara, Turkey

PIH8

COMPARATIVE PHARMACOECONOMIC STUDY OF DISPOSABLE AND REUSABLE GOWNS AND DRAPES

 

Yagudina R1, Kulikov A2, Metelkin I2
1First Moscow State Medical University named after I. M. Sechenov, Moscow, Moscow, Russia, 2First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia

PIH9

COMPARE HEALTH CARE UTILIZATION AND COSTS AMONG MENOPAUSAL WOMEN WITH DIFFERENT SYMPTOMS BY LINKING WOMEN'S REGISTRY AND CLAIMS DATABASE

 

Xie L1, Du J1, Altinbas S2, Baser O3
1STATinMED Research, Ann Arbor, MI, USA, 2Etlik Zübeyde Haným Women's Health Teaching and Research Hospital, Ankara, Turkey, 3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA

PIH10

COST EFFECTIVENESS COMPARISON BETWEEN DIENOGEST AND GONADOTROPIN-RELEASING HORMONE ANALOGS IN TURKEY

 

Marmarali B1, Deger C1, Memis SA1, Parali E1, Sumer F1, Karakeben K1, Kayadibinli M2
1Bayer Türk, Istanbul, Turkey, 2STATinMED Research, Istanbul, Turkey

PIH11

COST OF UNINTENDED PREGNANCY IN THE UNITED KINGDOM: A ROLE FOR INCREASED USE OF LONG-ACTING REVERSIBLE CONTRACEPTIVE METHODS

 

Hassan F1, Henry N1, Wichmann K2, Priaulx J3, Filonenko A2
1IMS Health, London, UK, 2Bayer Pharma AG, Berlin, Germany, 3Bayer HealthCare, New Bury, West Berkshire, UK

PIH12

BURDEN OF EARLY-ONSET NEONATAL SEPSIS IN THE RUSSIAN FEDERATION

 

Soldatova I1, Pankratyeva L2, Avxentyeva M1, Omelyanovsky V1
1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia, 2Russian National Research Medical University, Moscow, Russia

PIH13

THE COSTS OF UNINTENDED PREGNANCY IN RUSSIA

 

Ignateva V, Krysanov I, Khachatryan G
Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia

PIH14

COST OF ILLNESS IN WOMEN WITH ENDOMETRIOSIS

 

Boström P1, Lövkvist L1, Gustafsson M2, Alexandersson O3, Bruse C4, Liffner C5, Holmberg J6, Edlund M1, Olovsson M7
1Bayer AB, Solna, Sweden, 2Kungsbacka Hospital, Kungsbacka, Sweden, 3Östersund Hospital, Östersund, Sweden, 4Karolinska University Hospital, Stockholm, Sweden, 5The Endometriosis Association, Sweden, Västerås, Sweden, 6Höglandssjukhuset, Eksjö, Sweden, 7Uppsala University Hospital, Uppsala, Sweden

PIH15

PRESCRIBING COST OF ENZYMES OVER A TWO-YEAR PERIOD USING A MEDICAL INSURANCE CLAIMS DATABASE

 

Truter I1, Graz CJM2
1Nelson Mandela Metropolitan University, Port Elizabeth, Eastern Cape, South Africa, 2Biophys Limited, Lydney, UK

PIH16

EPIDEMIOLOGY OF HERPES ZOSTER AND ITS RELATED RESOURCE UTILIZATION: A LARGE POPULATION-BASED STUDY IN ISRAEL

 

Weitzman D1, Shavit O2, Stein M2, Shay N2, Cohen R2, Chodick G1, Shalev V1
1Maccabi Healthcare Services, Tel Aviv, Israel, 2Merck Sharp & Dohme (MSD) Israel, Ltd., Hod HaSharon , Israel

PIH17

COST BENEFIT ANALYSIS ON THE LONG TERM EFFECTS OF IN VITRO FERTILIZATION (IVF) IN GREECE: AN ANALYSIS BASED ON A LIFETIME MODEL

 

Fragoulakis V, Maniadakis N
National School of Public Health, Athens, Greece

PIH18

CLINICAL EFFICACY AND COST-EFFECTIVENESS OF ADDITIONAL IMMUNOTHERAPY IN EARLY-ONSET NEONATAL INFECTIONS

 

Soldatova I1, Pankratyeva L2, Degtyareva M2, Volodin N3
1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia, 2Russian National Research Medical University, Moscow, Russia, 3Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

PIH19

COST EFFECTIVENESS OF PREMALEX (ESCITALOPRAM) COMPARED TO SERTRALINE FOR TREATMENT OF PMDD (PREMENSTRUAL DYSPHORIC DISORDER), BASED UPON THE CGI-S

 

Björk-Linné A1, Borg S2, Eriksson E3, Velin B1
1H. Lundbeck AB, Helsingborg, Sweden, 2The Swedish Institute for Health Economics, Lund, Sweden, and Faculty of Medicine, Lund University, Lund, Sweden, Lund, Sweden, 3University of Gothenburg, Gothenburg, Sweden

PIH20

COST-EFFECTIVENESS OF SUPPLEMENTAL N-3 IN TOTAL PARENTERAL NUTRITION THERAPY IN THE ITALIAN, FRENCH, GERMAN AND UK CONTEXT: A DISCRETE EVENT SIMULATION MODEL

 

Pradelli L1, Eandi M2, Povero M1, Mayer K3, Heller AR4, Muscaritoli M5
1AdRes HE&OR, Turin, Italy, 2University of Torino, Torino, Italy, 3Justus-Liebig University Giessen, Giessen, Germany, 4Universitätsklinikum Carl Gustav Carus at the Technical University Dresden, Dresden, Germany, 5University La Sapienza, Roma, Italy

PIH21

HEALTH ECONOMIC EVIDENCE IN SUPPORT OF A LOW-DOSE CONTRACEPTIVE LEVONORGESTREL INTRAUTERINE SYSTEM (LNG-IUS 12)

 

Trussell J1, Hassan F2, Henry N2, Law A3, Pocoski J3, Filonenko A4
1Princeton University, Princeton, NJ, USA, 2IMS Health, London, UK, 3Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 4Bayer Pharma AG, Berlin, Germany

PIH22

CLINICAL EFFICACY AND COST-EFFECTIVENESS OF HUMAN RECOMBINANT INTERFERON-α2B IN NEONATAL INFECTIONS

 

Soldatova I1, Pankratyeva L2
1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia, 2Russian National Research Medical University, Moscow, Russia

PIH23

A DISCRETE EVENT SIMULATION MODEL USED FOR PHARMACOECONOMIC EVALUATION OF OMEGAVEN® IN THE CHINESE SETTING

 

Hu SL1, Pradelli L2, Luo L3, Liu F3, Kulkarni H4, Dai Y4
1Center for Health Development Research, Shanghai Bureau of Health, School of Public Health, Fudan University, Shanghai, China, 2AdRes HE&OR, Turin, Italy, 3Fudan University, Shanghai, China, 4Fresenius Kabi Asia Pacific Ltd., Hong Kong, Hong Kong

PIH24

ECONOMIC EVALUATION OF ULIPRISTAL ACETATE TABLETS FOR THE TREATMENT OF PATIENTS WITH MODERATE AND SEVERE SYMPTOMS OF UTERINE FIBROIDS

 

Nagy B1, Tímár G2, Jozwiak-Hagymásy J2, Kovacs G2, Merész G2, Vámossy I3, Agh T4, László Á5, Vokó Z1, Kalo Z6
1ELTE, Budapest, Hungary, 2Syreon Research Institute, Budapest, Hungary, 3Gedeon Richter Plc., Budapest, Hungary, 4Semmelweis University, Budapest, Hungary, 5Bajcsy-Zsilinszky Hospital, Budapest, Hungary, 6Eötvös Loránd University, Budapest, Hungary

PIH25

TESTOSTERONE REPLACEMENT THERAPY IN MALES WITH HYPOGONADISM IN SWEDEN: A COST-EFFECTIVENESS ANALYSIS

 

Arver S1, Fraschke A2, Luong B3, Ghatnekar O4, Stanisic S5, Mueller E5
1Karolinska Institutet, Stockholm, Sweden, 2Bayer AB, Solna, Sweden, 3Bayer Pharma AG, Berlin, Berlin, Germany, 4The Swedish Institute for Health Economics, Lund, Skåne, Sweden, 5Analytica LA-SER International Inc., Loerrach, Germany

PIH26

SOCIAL IMPACT OF ADALIMUMAB IN THE ITALIAN PERSPECTIVE

 

Marcellusi A1, Gitto L2, Giannantoni P2, Russo S3, Mennini FS2
1University of Rome, Rome, Italy, Italy, 2University of Rome, Rome, Italy, 3University of Rome , Rome, Italy

PIH27

COST ANALYSIS OF NEONATAL AND PEDIATRIC PARENTERAL NUTRITION IN BELGIUM

 

Walter E1, Dragosits A1, Noerens K2, De Bosscher H3, Blom H3, Maton P4
1Institute for Pharmaeconomic Research, Vienna, Austria, 2UZ Brussel, Brussels, Belgium, 3UZ Antwerpen, Edegem, Belgium, 4Clinique Saint-Vincent, Rocourt, Belgium

PIH28

THE PROJECT SINCOPE IN TRIVENETO (PROSIT) STUDY. A MULTICENTER STUDY REGARDING SYNCOPE MANAGEMENT IN AN ITALIAN REGION

 

Molon G1, Costa A1, De Biasi A2, Tenci A3, Valle R4, Tiozzo A4, Catanzariti D5, Bertagnolli C6, Sitta N7, Di Chiara A8, Pillini PP9, Zorzi A10, Mignoli S6, Borghetti F11
1Ospedale Sacro Cuore Don Calabria, Negrar, Italy, 2Azienda ULSS 1 Belluno, Belluno, Italy, 3Ospedale Frà Castoro San Bonifacio, Verona, Italy, 4Ospedale Civile, Chioggia, Italy, 5Ospedale S. Maria del Carmine, Rovereto, Italy, 6Ospedale di Cles, Cles, Italy, 7Presidio Ospedaliero di Conegliano ULSS 7, Conegliano, Italy, 8Ospedale Sant'Antonio Abate, Tolmezzo, Italy, 9Ospedale Sant'Antonio Abate di Tolmezzo, Tolmezzo, Italy, 10Ospedale Frà Castoro, San Bonifacio-Verona, Italy, 11Medtronic Italia, Sesto San Giovanni, Italy

INDIVIDUAL’S HEALTH – Patient-Reported Outcomes & Patient Preference Studies

PIH29

IDENTIFICATION OF FACTORS AND THEIR INFLUENCE ON PATIENT ADHERENCE TO INTRAVENOUS MEDICATION FOR CHRONIC CONDITIONS: FINDINGS OF A LITERATURE REVIEW IN OSTEOPOROSIS AND CROHN'S DISEASE

 

Williams AE, Oldman AH
MedImmune, Cambridge, Cambs, UK

PIH30

POTENTIALLY INAPPROPRIATE PRESCRIBING AND ADVERSE HEALTH OUTCOMES IN COMMUNITY DWELLING OLDER POPULATIONS

 

Cahir C1, Fahey T2, Teljeur C3, Bennett K1
1Trinity Centre for Health Sciences, Dublin, Ireland, 2Royal College of Surgeons in Ireland, Dublin, Ireland, 3Health Information and Quality Authority, Dublin, Ireland

PIH31

INTENTIONAL AND UNINTENTIONAL NON-ADHERENCE DIFFER ACROSS PREVALENT CONDITIONS IN A RUSSIAN PATIENT POPULATION

 

Goren A1, Isherwood G2, Vietri J3
1Kantar Health, New York, NY, USA, 2Kantar Health, Epsom, Surrey, UK, 3Kantar Health, Princeton, NJ, USA

PIH32

THE IMPACT OF PERIODS ON WOMEN'S QUALITY OF LIFE IN WOMEN REPORTING A PROBLEM

 

Pumford N1, Muston D2, Wade A1, Crawford G1, Young D3
1Patients Direct, Glasgow, UK, 2Bayer Plc, Newbury, UK, 3University of Strathclyde, Glasgow, UK

PIH33

UTILITY AND HUMAN CAPITAL LOSS IN ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND RHEUMATOID ARTHRITIS – THE IMPACT OF PREVALENCE, DISEASE SPECIFIC MORTALITY AND UTILITY DECREMENT ON OVERALL HEALTH BURDEN

 

Meszaros A1, Agh T1, Inotai A2
1Semmelweis University, Budapest, Hungary, 2Syreon Research Institute, Budapest, Hungary

PIH34

WITHDRAWN

 

PIH35

DISABILITY-ADJUSTED-LIFE-YEARS (DALYS) LOSS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS:

 

Darba J1, Kaskens L2, Perez-Alvarez N2, Palacios S3, Neyro JL4, Rejas J5
1Universitat de Barcelona, Barcelona, Spain, 2BCN Health, Barcelona, Spain, 3Instituto Palacios de Salud y Medicina de la Mujer, Madrid, Spain, 4Hospital Universitario Cruces, Baracaldo (Vizcaya), Spain, 5Pfizer España, Alcobendas/Madrid, Spain

PIH36

QUALITY OF LIFE OF MEDICAL UNIVERSITY OF WARSAW FACULTY OF PHARMACY STUDENTS IN 2010-2012

 

Zawodnik S1, Krancberg AN1, Hermanowski TR1, Quality of Life Students Working Group QOLSWG2
1Medical University of Warsaw, Warsaw, Poland, 2Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland

PIH37

TRENDS OF QUALITY OF LIFE IN SOUTH KOREAN ADULTS DURING 2007-2010

 

Chang CW1, Choi IS1, Lee SM2, Suh DC3
1Rutgers University, Piscataway, NJ, USA, 2Chung-Ang University, Seoul, South Korea, 3College of Pharmacy, Chung-Ang University, Seoul, NJ, South Korea

PIH38

CAPTURING QUALITY OF LIFE IN CONDITIONS WITH FLUCTUATING SYMPTOMS

 

Pumford N, Crawford G, Wade A
Patients Direct, Glasgow, UK

PIH39

OCCUPATIONAL STRESS AND BURNOUT: IMPACT ON THE ATTITUDES OF PHARMACISTS IN PROVIDING PHARMACEUTICAL SERVICES

 

Jocic D, Krajnovic D, Lakic D, Tasic L
University of Belgrade – Faculty of Pharmacy, Belgrade, Serbia and Montenegro

PIH40

WHAT DO HEALTH ECONOMISTS EXPECT FROM THEIR EMPLOYER- RESULTS FROM AN ON-LINE SURVEY IN GERMANY

 

Mahlich JC1, Morfeld JC2
1Janssen-Cilag GmbH, Neuss, Nordrhein-Westfa, Germany, 2Universität zu Köln, Cologne, Germany

INDIVIDUAL’S HEALTH – Health Care Use & Policy Studies

PIH41

LONG-TERM FISCAL IMPLICATIONS OF FUNDING ASSISSTED REPRODUCTIVE THERAPIES: REVIEW OF THE LITERATURE

 

Pérez-Camarero S1, Ivanova A1, García-Jurado L2, Polanco C2, Hidalgo A3
1Instituto Max Weber, Majadahonda, Madrid, Spain, 2Merck SL, Madrid, Spain, 3Castilla-La Mancha University, Toledo, Spain

PIH42

EFFECTIVENESS OF A PROTOCOL FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) IMMUNOPROPHYLAXIS IN PRE-TERM INFANTS BORN AT

 

Flores S1, Fernandez Perez A2, Lozada A3, Bautista J4
1Hospital Universitario Virgen del Rocio, Seville, Spain, 2Virgen Del Rocio University Hospital, sevilla, Spain, 3Virgen del Rocio University Hospital, sevilla, Spain, 4Virgen del Rocío University Hospital, Sevilla, Spain

PIH43

COMPARISON OF UNINTENDED PREGNANCY RATES AMONG WOMEN WHO INITIATED ORAL CONTRACEPTIVE THERAPY WITH A 84/7 ESTRADIOL OR A 84/7 PLACEBO

 

Brewster C1, Lage MJ2, Grubb E1
1Teva Pharmaceuticals, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, Delray Beach, FL, USA

PIH44

CONTRACEPTIVE UTILIZATION IN WOMEN WHO HAD AN ABORTION: A CANADIAN COHORT-STUDY

 

Goyette A
Merck Canada Inc., Kirkland, QC, Canada

PIH45

COMPARISON OF UNINTENDED PREGNANCY RATES IN USERS OF 84/7, 21/7, AND 24/4 ORAL CONTRACEPTIVE REGIMENS

 

Brewster C1, Lage MJ2, Grubb E1
1Teva Pharmaceuticals, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, Delray Beach, FL, USA

PIH46

OUTCOMES OF DRUG USE DURING PREGNANCY: A NOVEL DATABASE IN THE NETHERLANDS TO STUDY DRUGS RISK ON THE YET UNBORN

 

Houweling LMA1, Hukkelhoven CWPM2, Schiere AM2, Van Wijngaarden RPT1, Herings RMC1
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2The Netherlands Perinatal Registry, Utrecht, The Netherlands

PIH47

ANALYSIS OF THE FORMULARY PROVISION OF CHILDREN IN UKRAINE

 

Kacheray Y1, Zalis'ka O1, Chavus H2
1Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, 2Pharmacy , Lviv, Ukraine

PIH48

SERVICE USES AND COSTS OF CHILD AND ADOLESCENT PSYCHIATRIC PATIENTS TREATED WITH ANTIPSYCHOTICS IN TAIWAN

 

Chang HC1, McCrone P1, Su KP2
1King's College London, London, UK, 2China Medical University, Taichung, Taiwan

PIH49

POPULATION ACCESS TO ROTAVIRUS VACCINATION IN DEVELOPPED COUNTRIES: LESSONS LEARNED FROM CURRENT EXPERIENCE AND POTENTIAL IMPLICATIONS FOR THE FUTURE

 

Toumi M1, Aballea S2, Millier A2, Duvillard R2
1University Claude Bernard Lyon 1, Lyon, France, 2Creativ-Ceutical, Paris, France

PIH50

TRENDS IN POST-MARKETING COMMITMENTS RELATED TO PREGNANCY AND LACTATION

 

Albano JD1, Roberts SS2, Benter U3, Whitehouse J4
1INC Research LLC, Raleigh, NC, USA, 2University of North Carolina, Wilmington, Wilmington, NC, USA, 3INC Research LLC, Munich, Germany, 4INC Research LLC, Wilmington, NC, USA

PIH51

REVIEW OF ALL PRODUCTS AUTHORIZED BY THE EUROPEAN MEDICINES AGENCY FROM 1995 TO 2011 IN REGARD TO PEDIATRIC INVESTIGATION PLAN APPLICATIONS

 

Mouchet J1, Acquadro C1, Emery MP1, Maier W2
1MAPI Research Trust, Lyon, France, 2Registrat-Mapi, London, UK

SESSION V – WEDNESDAY, 7 NOVEMBER
SET-UP: Wednesday, 7 November, 8:30-8:45
POSTER DISPLAY HOURS: Wednesday, 7 November, 8:45-14:45
POSTER AUTHOR DISCUSSION HOUR: Wednesday, 7 November, 12:45-13:45
DISMANTLE: Wednesday, 7 November, 14:45

NEUROLOGICAL DISORDERS – Clinical Outcomes Studies

PND1

12-MONTH CLINICAL EVOLUTION OF MODERATE ALZHEIMER'S DISEASE PATIENTS IN SPAIN: THE EVOCOST STUDY

 

Frank-Garcia A1, Salva A2, LeReun C3, Gimeno V4, Milea D5, Bineau S5
1Universidad Autónoma de Madrid, Madrid, Spain, 2Universitat Autònoma de Barcelona, IIB - Sant Pau, Barcelona, Spain, 3Independent Biostatistician, Carrigaline county, Cork, Ireland, 4Lundbeck España S.A., Barcelona, Spain, 5Lundbeck S.A.S., Issy-Les-Moulineaux, France

PND2

EFFECT OF COGNITIVE BEHAVIOURAL THERAPY IN MULTIPLE SCLEROSIS FATIGUE: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS

 

Kohli IS, Kataria A, Singla S, Kaushik P, Jindal R, Aggarwal A
Heron Health Private Ltd., Chandigarh, India

PND3

RELAPSES REQUIRING INTRAVENOUS STEROIDS AND MULTIPLE SCLEROSIS-RELATED HOSPITALIZATIONS: FINDINGS FROM THE PHASE 3 DEFINE AND CONFIRM STUDIES

 

Havrdova E1, Gold R2, Fox RJ3, Kappos L4, Kita M5, Sarda SP6, Yang M6, Zhang R6, Dawson KT6, Viglietta V6, Sheikh SI6, Giovannoni G7
1Department of Neurology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 2St Josef Hospital, Ruhr University, Bochum, Germany, 3Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA, 4University Hospital, Basel Neurology, Basel, Switzerland, 5Virginia Mason Medical Center, Seattle, WA, USA, 6Biogen Idec Inc., Weston, MA, USA, 7Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK

PND4

CAPSAICIN 8% PATCH MONOTHERAPY FOR TREATMENT OF POST-HERPETIC NEURALGIA: INTEGRATED ANALYSIS OF PHASE III STUDIES

 

Poole CD1, Chambers C2, Currie CJ3, Odeyemi IA4
1Cardiff University, Cardiff, UK, 2Astellas Pharma Europe Ltd., Staines, UK, 3Cardiff University, Cardiff, UK, 4Astellas Pharma Europe Ltd., Middlesex , UK

PND5

A MIXED TREATMENT COMPARISON OF GABAPENTIN ENACARBIL, PRAMIPEXOLE, ROPINIROLE AND ROTIGOTINE IN MODERATE-TO-SEVERE RESTLESS LEGS SYNDROME (RLS)

 

Sun Y1, van Valkenhoef G2, Morel T3
1Deloitte, Diegem, Belgium, 2University of Groningen, Groningen, The Netherlands, 3KU Leuven, Leuven, Belgium

PND6

COMBINING RCT AND OBSERVATIONAL DATA IN A MIXED TREATMENT COMPARISON OF DISEASE-MODIFYING-THERAPIES FOR MULTIPLE SCLEROSIS

 

Fogarty E1, Schmitz S2, Walsh C3, Barry M4
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin, Dublin, Ireland, 3Trinity College Dublin, Dublin, Ireland, 4St. James's Hospital, Dublin, Ireland, Ireland

PND7

OFF-LABEL USE OF ANTIEPILEPTIC DRUGS AND ITS COSTS – A DRUG UTILIZATION STUDY IN PORTUGAL

 

Afonso-Silva M, Oliveira-Martins S, Cabrita J
Faculty of Pharmacy of the University of Lisbon, Lisbon, Lisbon, Portugal

PND8

PREVALENCE AND INCIDENCE RATES OF MULTIPLE SCLEROSIS IN THE UNITED STATES

 

Baser O1, Wang L2, Li T3, Shu Z3, Xie L4
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 3STATinMED (BeiJing) International Healthcare Technology Assessment Co., Ltd., BeiJing, China, 4STATinMED Research, Ann Arbor, MI, USA

PND9

FREQUENCY AND IMPACT OF RELAPSES IN GERMAN PATIENTS WITH MULTIPLE SCLEROSIS BASED ON A LONGITUDINAL POPULATION-BASED STUDY

 

Schmidt J1, Dippel FW2, Kuehne S3, Holz B4, Larisch K5
1TU München, Garching, Germany, 2Sanofi Deutschland GmbH, Berlin, Germany, 3Sanofi-Aventis Deutschland GmbH, Berlin, Germany, 4Genzyme GmbH, Neu Isenburg, Germany, 5Gesundheitsforen Leipzig GmbH, Büro München, München, Germany

PND10

FASTER COGNITIVE DECLINE IS ASSOCIATED WITH DECREASING SURVIVAL IN PATIENTS WITH ALZHEIMER'S DISEASE

 

van Sanden S1, Diels J2, Gaudig M3, Spencer M4, Thompson G5, Arrighi HM6
1EMEA HEMAR Analytics, Janssen EMEA, Beerse, Belgium, 2Janssen Pharmaceutica, Beerse, Belgium, 3Janssen Alzheimer Immunotherapy, Dublin, Ireland, 4Janssen-Cilag Limited, High Wycombe, Bucks, UK, 5Janssen-Cilag Ltd., High Wycombe, UK, 6Janssen Alzheimer Immunotherapy, San Francisco, CA, USA

PND11

ESTIMATING SURVIVAL-BENEFIT OF NEW THERAPEUTIC INTERVENTIONS IN CYSTIC FIBROSIS PATIENTS IN GERMANY, FRANCE, UK AND IRELAND

 

Becker CC, Kim M, Johnson C
Vertex Pharmaceuticals, Cambridge, MA, USA

NEUROLOGICAL DISORDERS – Cost Studies

PND12

BUDGET IMPACT ANALYSIS OF ROUTINE TESTING FOR GENETICALLY BASED CARDIOPATHIES ASSOCIATED WITH HIGH RISK OF SUDDEN DEATH IN SPAIN: PRELIMINARY RESULTS

 

Fernández I1, García-Pavía P1, Ripoll T2, Boldeanu A3, Gracia A4, Ramírez de Arellano A4, Aceituno S5, Lizán L5, Puig-Gilberte J6, Salas E6
1Hospital Universitario Puerta del Hierro, Madrid, Spain, 2Hospital Son Llàtzer, Palma de Mallorca, Spain, 3FERRER-inCode, Barcelona, Spain, 4Ferrer Grupo, Barcelona, Spain, 5Outcomes 10, Castellón, Spain, 6GENDIAG, Barcelona, Spain

PND13

BUDGET IMPACT ANALYSIS AND UPDATE OF A COST EFFECTIVENESS EVALUATION FOR ALPHA (α ) POLYMORPH RIFAXIMIN FOR THE TREATMENT OF ACUTE HEPATIC ENCEPHALOPATHY

 

Cardona DP1, Zapata L2, Ceballos M1, Diez F3, Rico I2, Zavala A3
1Universidad De Antioquia- Facultad De Quimica Farmaceutica, MEDELLIN, ANTIOQUIA, Colombia, 2Guia Mark, Mexico, DF, Mexico, 3Guia Mark, México, DF, Mexico

PND14

BUDGETARY IMPACT OF THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

 

García-Ruiz AJ1, Izquierdo Ayuso G2, Garcia-Agua Soler N3
1Malaga University, Malaga, Spain, 2Universitary Hospital , Seville, Spain, 3University of Malaga, Malaga, Spain

PND15

COST-EFFECTIVENESS OF BUCCOLAM® (LICENSED OROMUCOSAL MIDAZOLAM) COMPARED TO BENZODIAZEPINES FOR THE TREATMENT OF ACUTE PROLONGED EPILEPTIC SEIZURES IN GERMANY

 

Lee D, Gladwell D, Batty A, Brereton NJ
BresMed, Sheffield, UK

PND16

COST-EFFECTIVENESS ANALYSIS OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL-ONSET SEIZURES IN MEXICO

 

Aguirre A1, Sentíes H2, Córdova S3, Benitez A1
1UCB de México, Mexico City, D.F., Mexico, 2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, DF, Mexico, 3Hospital Español de México, Mexico City, DF, Mexico

PND17

COMPARING COST OF THERAPEUTIC PLASMA EXCHANGE AND INTRAVENOUS IMMUNOGLOBULIN INFUSION IN TREATING GUILLAIN-BARRé SYNDROME

 

Atikeler K1, Tuna E2, Kockaya G3
1Ankara University, Ankara, Turkey, 2Hacettepe University, Ankara, Turkey, 3Health Economics and Policy Association, Ankara, Turkey

PND18

IMPACT OF CO-MORBIDITIES ON THE ECONOMIC BURDEN OF PARKINSON'S DISEASE IN GERMANY POST-2000

 

Takyar S, Kataria A, Rajput A, Kaur M
Heron Health Pvt. Ltd., Chandigarh, India

PND19

PHARMACOLOGICAL COSTS OF RECURRENT-REMITENT MULTIPLE SCLEROSIS TREATMENT IN SPAIN

 

Polanco C1, Sanz-Granda Á2, García-Jurado L1
1Merck SL, Madrid, Spain, 2WEyS, Majadahonda, Madrid, Spain

PND20

12-MONTH COST OF ILLNESS STUDY OF MODERATE ALZHEIMER'S DISEASE PATIENTS IN SPAIN: THE EVOCOST STUDY

 

Salva A1, Frank-Garcia A2, LeReun C3, Gimeno V4, Milea D5, Bineau S5
1Universitat Autònoma de Barcelona, IIB - Sant Pau, Barcelona, Spain, 2Universidad Autónoma de Madrid, Madrid, Spain, 3Independent Biostatistician, Carrigaline county, Cork, Ireland, 4Lundbeck España S.A., Barcelona, Spain, 5Lundbeck S.A.S., Issy-Les-Moulineaux, France

PND21

MULTIPLE SCLEROSIS IN RUSSIAN FEDERATION: EVALUATION OF SOCIAL AND ECONOMICAL BURDEN IN REAL CLINICAL PRACTICE

 

Yagudina R1, Kulikov A2, Litvinenko M2
1First Moscow State Medical University named after I. M. Sechenov, Moscow, Moscow, Russia, 2First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia

PND22

DESCRIPTIVE ANALYSIS OF THE DIRECT COSTS OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE MEXICAN SETTING

 

Pizarro M1, Soto H2, Carbajal A3
1Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, 2Iteliness Consulting, México DF, Distrito Federal, Mexico, 3Centro Medico Nacional Siglo XX!, Mexico City, Mexico

PND23

ECONOMIC BURDEN OF ILLNESS FOR PERSONS WITH SPINA BIFIDA (SB) IN GERMANY

 

van Nooten F1, Winnette R1, Stein R2, Lindemann M3, Joeckel M2, Raluy M1, Lambrelli D1, Eriksson D1, Wasiak R1
1United BioSource Corporation, London, United Kingdom, 2University of Medicine, Johannes Gutenberg University Mainz, Mainz, Germany, 3Bayer Pharma, Berlin, Germany

PND24

METHODOLOGICAL CONSIDERATIONS IN COST OF ILLNESS STUDIES ON ALZHEIMER DISEASE

 

Costa N1, Derumeaux-Burel H2, Rapp T3, Garnault V2, Ferlicoq L2, Gillette S2, Andrieu S1, Vellas B2, Lamure M4, Grand A2, Molinier L5
1INSERM, Toulouse, France, 2University hospital of Toulouse, Toulouse, France, 3University of Paris Descartes, Paris, France, 4University of Lyon, Bron, France, 5INSERM-University Hospital of Toulouse, Toulouse, France

PND25

BURDEN OF SPINA BIFIDA (SB) IN GERMANY - THE CHARACTERISTICS OF SB POPULATION

 

Schroeder A1, Joeckel M1, van Nooten F2, Lindemann M3, Lambrelli D4, Eriksson D4, Raluy M4, Wasiak R4, Stein R1
1University of Medicine, Johannes Gutenberg University Mainz, Mainz, Germany, 2Astellas Pharma Europe B.V., Leiderdorp, The Netherlands, 3Bayer Pharma AG, Berlin, Germany, 4United BioSource Corporation, London, UK

PND26

TREATMENT PATTERNS AND RESOURCE CONSUMPTION IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)-RELATED SPASTICITY IN GERMANY - RESULTS OF MOVE 1 STUDY

 

Ehlken B1, Flachenecker P2, Zettl U3, Essner U4, Henze T5
1IMS Health, Munich, Germany, 2Neurological Centre for Rehabilitation - Quellenhof, Bad Wildbad, Germany, 3University Hospital, Rostock, Germany, 4Almirall Hermal GmbH, Reinbek, Germany, 5Centre for Rehabilitation, Nittenau, Germany

PND27

ASSESSMENT OF INFORMAL CARE PROVIDED TO PATIENTS WITH MULTIPLE SCLEROSIS AND LIMITATION OF PERSONAL AUTONOMY

 

Aranda I1, Oliva J1, Hidalgo A1, González A2, Vilaplana C3, Polanco C4
1Castilla-La Mancha University, Toledo, Spain, 2Instituto Max Weber, Majadahonda, Madrid, Spain, 3Universidad Católica San Antonio de Murcia, Guadalupe, Murcia, Spain, 4Merck SL, Madrid, Spain

PND28

HEALTH CARE COSTS OF MULTIPLE SCLEROSIS IN GERMANY

 

Hapfelmeier A1, Dippel FW2, Schinzel S3, Holz B4, Seiffert A5
1TU München, Garching, Germany, 2Sanofi Deutschland GmbH, Berlin, Germany, 3Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany, 4Genzyme GmbH, Neu Isenburg, Germany, 5Gesundheitsforen Leipzig GmbH, Leipzig, Germany

PND29

COST EVALUATION OF MULTIPLE SCLEROSIS AT DIFFERENT STAGES IN IRAN

 

Khanizadeh H
USM, PENANG, OTHER, Malaysia

PND30

COST ANALYSIS OF GLATIRAMER ACETATE VERSUS FINGOLIMOD FOR THE TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

 

Sánchez-de la Rosa R1, Sabater E2, Casado MA3
1TEVA Pharma SLU, Madrid, Spain, 2Pharmacoeconomics & Outcomes Research Iberia, Pozuelo, Spain, 3Pharmacoeconomics & Outcomes Research Iberia, Madrid, Madrid, Spain

PND31

ECONOMIC VALUE OF SLOWING PARKINSON'S DISEASE IN GERMANY: MODELING PROGRESSION THROUGH HOEHN AND YAHR STAGES

 

Johnson S1, Birnbaum HG1, Kaltenboeck A2, Diener M2, Siderowf A3
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Inc., New York, NY, USA, 3University of Pennsylvania, Philadelphia, PA, USA

PND32

ECONOMIC EVALUATION OF NATALIZUMAB FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN MEXICO

 

Reyes A1, Sánchez-Mejorada G2, Trejo W2
1RCEI Consulting, MEXICO, D F, Mexico, 2STENDHAL, MEXICO, D F, Mexico

PND33

COST-EFFECTIVENESS ANALYSIS OF GENETIC TESTING OF FIRST-DEGREE RELATIVES AT RISK OF SUDDEN CARDIAC DEATH DUE TO GENE-RELATED CARDIOPATHIES IN SPAIN: PRELIMINARY RESULTS

 

Fernández I1, García-Pavía P1, Ripoll T2, Boldeanu A3, Gracia A4, Ramírez de Arellano A4, Paz S5, Lizán L5, Puig-Gilberte J6, Salas E6
1Hospital Universitario Puerta del Hierro, Madrid, Spain, 2Hospital Son Llàtzer, Palma de Mallorca, Spain, 3FERRER-inCode, Barcelona, Spain, 4Ferrer Grupo, Barcelona, Spain, 5Outcomes 10, Castellón, Spain, 6GENDIAG, Barcelona, Spain

PND34

LONG-TERM EFFECTS ON COSTS AND QUALITY ADJUSTED LIFE YEARS OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS TREATED WITH LAQUINIMOD: RESULTS BASED ON THE ALLEGRO AND BRAVO TRIALS

 

Lang A1, Tuomari A2, Kobelt G3, Lindgren P4
1OptumInsight, Stockholm, Sweden, 2Teva Pharmaceuticals, Malvern, PA, USA, 3European Health Economics, Speracedes, France, 4OptumInsight and Karolinska Institutet, Stockholm, Sweden

PND35

BUCCOLAM® (LICENSED OROMUCOSAL MIDAZOLAM) VERSUS RECTAL DIAZEPAM FOR ACUTE EPILEPTIC SEIZURES: ITALIAN COST-EFFECTIVENESS ANALYSIS

 

Gladwell D1, Aneli M2, Batty A1, Lee D1
1BresMed, Sheffield, UK, 2Keypharma SRL, Milan, Lombardy, Italy

PND36

COST-EFFECTIVENESS OF DIFFERENT INTERFERON-BETA THERAPIES FOR RELAPSING-REMITTING AND SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: A MARKOV MODEL BASED ON LONG-TERM CLINICAL DATA

 

Nikfar S1, Akbarisari A2, Kebriaee A2, Dinarvand R2, Abdollahi M2
1Tehran University of Medical Sciences, Tehran, Tehran, Iran, 2Tehran University of Medical Sciences, Tehran, Iran

PND37

THE COST-EFFECTIVENESS OF BUCCOLAM® (LICENSED OROMUCOSAL MIDAZOLAM) FOR THE TREATMENT OF ACUTE EPILEPTIC SEIZURES IN THE UNITED KINGDOM; A HYBRID MODEL SOLUTION

 

Lee D1, Batty A1, Gladwell D1, Brereton NJ1, Tate E2
1BresMed, Sheffield, UK, 2Hayward Medical Communications, Newmarket, Suffolk, UK

PND38

COST MINIMIZATION ANALYSIS OF FINGOLIMOD VERSUS NATALIZUMAB IN THE SECOND-LINE TREATMENT OF REMITTENT-RECURRENT MULTIPLE SCLEROSIS

 

Crespo C1, Izquierdo G2, García-Ruiz A3, Granell M4, Brosa M1
1Oblikue Consulting, Barcelona, Spain, 2Hospital Universitario Virgen de la Macarena Sevilla, Sevilla, SC, Spain, 3Malaga University, Malaga, Spain, 4Novartis Farmaceutica, Barcelona, Barcelona, Spain

PND39

COST-UTILITY ANALYSIS OF A THERAPEUTIC EDUCATION PROGRAM IN PARKINSON DISEASE VERSUS TRADITIONAL CARE

 

Costa N1, Derumeaux-Burel H2, Canivet C2, Ory F2, Brefel-Courbon C2, Molinier L3
1INSERM, Toulouse, France, 2University hospital of Toulouse, Toulouse, France, 3INSERM-University Hospital of Toulouse, Toulouse, France

PND40

COST-UTILITY ANALYSIS OF FINGOLIMOD IN BRAZILIAN PATIENTS WITH MULTIPLE SCLEROSIS

 

Silva NL1, Takemoto MLS2, Cruz RB2, Suzuki C3
1Novartis, Sao Paulo, Brazil, 2ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 3Novartis, São Paulo, Brazil

PND41

THE COST-EFFECTIVENESS OF BUCCOLAM FOR THE TREATMENT OF PROLONGED, ACUTE, CONVULSIVE EPILEPTIC SEIZURES IN SPAIN

 

Lopez-Bastida J1, Gil Aguirre A2, Lee D3
1Castilla-La Mancha University, Talavera de la Reina.
Toledo, Spain, 2Strategic Regulatory & Market Access Consulting, Barcelona, Spain, 3BresMed, Sheffield, UK

PND42

WITHDRAWN

 

 

PND43

COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES

 

Yakovlev MV1, Kulikov AU2, Sokov EL1, Kornilova LE1
1Peoples' Friendship University of Russia, Moscow, Russia, 2First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia

PND44

WITHDRAWN

 

 

PND45

DIFFERENTIAL OUTCOMES IN PATIENTS WITH ALZHEIMER'S DISEASE (AD) TREATED WITH DONEPEZIL 23

 

Copher R1, Li X1, Powers A1, Clionsky E2
1Eisai, Inc., Woodcliff Lake, NJ, USA, 2Clionsky Neuro Systems, Inc, Springfield, MA, USA

NEUROLOGICAL DISORDERS – Patient-Reported Outcomes & Patient Preference Studies

PND46

RELATIONSHIP BETWEEN PATIENT ADHERENCE TO TREATMENT AND SPANISH HOSPITAL PHARMACY'S UNMET NEEDS FOR THE MANAGEMENT OF MULTIPLE SCLEROSIS

 

Balaña M1, Lahoz R2, Monte E3, Lorente L3, García Fernández J4, Garcia Monsalve A5, Olatz Ibarra M6, Granell M1, Blanco J1
1Novartis Farmaceutica, Barcelona, Barcelona, Spain, 2Novartis Farmaceutica, Barcelona, Spain, 3Hospital Universitario La Fe, Valencia, Valencia, Spain, 4C. M. de Orense, Orense, Orense, Spain, 5Hospital Vega Baja, Orihuela, Alicante, Spain, 6Hospital Galdakao, Galdakao, Bizkaia, Spain

PND47

ASSESSMENT OF QUALITY OF LIFE OF AUSTRALIANS WITH YOUNG ONSET PARKINSON'S DISEASE

 

Ortiz MS1, Partridge E2, Hawthorne G3, Dixon M4
1University of NSW, Darlinghurst, NSW, Australia, 2University of Technology,, Ultimo, NSW, Australia, 3The University of Melbourne, Melbourne, VIC, Australia, 4Parkinson's NSW, North Ryde, NSW, Australia

PND48

HEALTH STATE VALUES IN ALZHEIMER'S DISEASE – BASELINE RESULTS FROM A LARGE PROSPECTIVE OBSERVATIONAL STUDY IN THREE EUROPEAN COUNTRIES (GERAS)

 

Reed C1, Argimon J2, Belger MA1, Bruno G3, Dodel R4, Happich M5, Haro JM6, Jones RW7, Vellas B8, Wimo A9
1Eli Lilly and Company, Windlesham, Surrey, UK, 2Servei Catala de la Salut, Barcelona, Spain, 3University of Rome, Rome, Italy, 4Philipps University, Marburg, Hessen, Germany, 5Eli Lilly and Company, Bad Homburg, Germany, 6Universitat de Barcelona, Barcelona, Spain, 7The Rice Centre, Royal United Hospital, Bath, UK, 8Toulouse University Hospital, Toulouse, France, 9Karolinska Institutet, Stockholm, Sweden

PND49

THE MEASUREMENT OF QUALITY OF LIFE IN CHILDREN WITH CYSTIC FIBROSIS WITH USING RUSSIAN VERSION OF HEALTH UTILITY INDEX (HUI) QUESTIONNAIRE

 

Gorinova Y, Simonova O, Vinyarskaya I, Samsonova M, Chernikov V
FSBI, Moscow, Russia

PND50

ESTIMATION OF THE EFFECT OF DALFAMPRIDINE EXTENDED RELEASE ON HEALTH UTILITY IN PATIENTS WITH MULTIPLE SCLEROSIS USING TWO EQUATIONS FOR MAPPING THE MSWS-12 TO THE EQ-5D

 

Limone B1, Sidovar M2, Gaebler JA3, Lee S1, Coleman CI4
1Hartford Hospital, Hartford, CT, USA, 2Acorda Therapeutics, Inc., Hawthorne, NY, USA, 3Biogen Idec Inc., Weston, MA, USA, 4University of Connecticut, Storrs, CT, USA

PND51

UTILITY MEASUREMENT IN EPILEPSY: EXPLORATORY ANALYSIS OF THE IMPACT OF SEIZURES ON CHILDREN

 

Batty A1, Lee D1, Gladwell D1, Brereton NJ1, Tate E2
1BresMed, Sheffield, UK, 2Hayward Medical Communications, Newmarket, Suffolk, UK

PND52

VALIDATION OF SPANISH VERSION OF THE HUNTINGTON CLINICAL SELF-REPORTED INSTRUMENT (H-CSRI)

 

Khemiri A1, Clay E2, Trigo P3, Yebenes J3, Dorey J4, Toumi M5
1Creativ-Ceutical, Tunis, Tunisia, 2Creativ-Ceutical, Paris, France, 3Hospital Ramón y Cajal, Madrid, Spain, 4Creativ Ceutical, Paris, France, 5University Claude Bernard Lyon 1, Lyon, France

PND53

PATIENT REPORTED SLEEP PROBLEMS IN THE UK

 

Wade A, Crawford G, Pumford N
Patients Direct, Glasgow, UK

PND54

FATIGUE AND QUALITY-OF-LIFE IN MULTIPLE SCLEROSIS PATIENTS WITH SPASTICITY IN GERMANY - RESULTS OF THE MOVE 1 STUDY

 

Pfiffner C1, Henze T2, Zettl U3, Essner U4, Flachenecker P5
1IMS Health GmbH & Co. OHG, Munich, Germany, 2Centre for Rehabilitation, Nittenau, Germany, 3University Hospital, Rostock, Germany, 4Almirall Hermal GmbH, Reinbek, Germany, 5Neurological Centre for Rehabilitation - Quellenhof, Bad Wildbad , Germany

PND55

MULTIPLE SCLEROSIS IMPACT SCALE (MSIS-29): ITS VALIDITY AND RESPONSIVENESS IN CLINICAL TRIAL-BASED SUBJECTS

 

Guo S1, Proskorovsky I2, Phillips GA3
1United BioSource Corporation, Lexington, MA, USA, 2United BioSource Corporation, Dorval, QC, Canada, 3Biogen Idec Inc., Weston, MA, USA

PND56

ASSESSING THE QUALITY OF LIFE IN A SPANISH POPULATION WITH MULTIPLE SCLEROSIS: THE SLIMS STUDY

 

Balaña M1, Lahoz R2, Hernández M3, Blanco J1
1Novartis Farmaceutica, Barcelona, Barcelona, Spain, 2Novartis Farmaceutica, Barcelona, Spain, 3Hospital Universitario Ntra.
Sra. de la Candelaria, Santa Cruz de Tenerife, Santa Cruz de Te, Spain

PND57

A MEASURE OF CARER QUALITY OF LIFE IN PARKINSON'S DISEASE (PDQ-CARER): DEVELOPMENT AND VALIDATION OF A SUMMARY INDEX SCORE

 

Jenkinson C1, Dummett S1, Dawson J2, Fitzpatrick R3, Kelly L1, Morley D1, Peters M1, Churchman D1
1University of Oxford, Oxford, UK, 2Health Services Research Unit, Department of Public Health, University of Oxford, Headington, Oxford, UK, 3Universtiy of Oxford, Oxford, Oxfordshire, UK

PND58

EFFECTS OF BG-12 ON QUALITY OF LIFE IN RELAPSING–REMITTING MULTIPLE SCLEROSIS: FINDINGS FROM THE PHASE 3 CONFIRM STUDY

 

Kita M1, Fox RJ2, Phillips JT3, Hutchinson M4, Havrdova E5, Sarda SP6, Kong J6, Viglietta V6, Sheikh SI6, Dawson KT6
1Virginia Mason Medical Center, Seattle, WA, USA, 2Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA, 3Multiple Sclerosis Program, Baylor Institute for Immunology Research, Dallas, TX, USA, 4St Vincent's University Hospital, Dublin, Ireland, 5Department of Neurology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 6Biogen Idec Inc., Weston, MA, USA

PND59

CROSS-CULTURAL VALIDATION OF THE HUNTINGTON'S DISEASE QUALITY OF LIFE BATTERY FOR CARERS IN FRANCE AND ITALY

 

Dorey J1, Aubeeluck A2, Squitieri F3, Clay E4, Stupple EJN5, De Nicola N3, Buchanan H6, Martino T7, Toumi M8
1Creativ Ceutical, Paris, France, 2University of Nottingham, Derby, UK, 3Neurogenetics and Rare Disease Centre, Pozzi, Italy, 4Creativ-Ceutical, Paris, France, 5University of Derby, Derby , UK, 6University of Nottingham, Nottingham, UK, 7AICH-Neuromed onlus, Pozzilli, Italy, 8University Claude Bernard Lyon 1, Lyon, France

PND60

NON-DIABETIC PERIPHERAL NEUROPATHIC PAIN IS UNDERDIAGNOSED IN GP PRACTICES ALTHOUGH IT HAS HIGH IMPACT ON PATIENTS' HEALTH RELATED QUALITY OF LIFE

 

Brodszky V1, Komoly S2, Bereczki D3, Embey-Isztin D4, Gulácsi L1, Balogh O1, V. Hevér N1, Torzsa P3, Péntek M1
1Corvinus University of Budapest, Budapest, Hungary, 2University of Pécs, Pécs, Hungary, 3Semmelweis University, Budapest, Hungary, 4National Institute of Oncology, Budapest, Hungary

PND61

QUALITY OF LIFE OF SPANISH FAMILY CARERS IN HUNTINGTON'S DISEASE

 

Urbinati D1, Dorey J2, Trigo P3, Yebenes J3, Toumi M4
1Creativ-Ceutical, Luxembourg, Luxembourg, 2Creativ Ceutical, Paris, France, 3Hospital Ramón y Cajal, Madrid, Spain, 4University Claude Bernard Lyon 1, Lyon, France

PND62

CARERS OF PEOPLE WITH PARKINSON'S DISEASE: FACTORS RELATED TO QUALITY OF LIFE

 

Morley D, Peters M, Dummett S, Kelly L, Churchman D, Dawson J, Fitzparick R, Jenkinson C
University of Oxford, Oxford, UK

PND63

EFFECTS OF BG-12 ON QUALITY OF LIFE IN RELAPSING–REMITTING MULTIPLE SCLEROSIS: FINDINGS FROM THE PHASE 3 DEFINE STUDY

 

Kappos L1, Gold R2, Arnold DL3, Bar-Or A3, Giovannoni G4, Selmaj K5, Sarda SP6, Agarwal S6, Zhang A6, Sheikh SI6, Dawson KT6
1University Hospital, Basel Neurology, Basel, Switzerland, 2St Josef Hospital, Ruhr University, Bochum, Germany, 3Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada, 4Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK, 5Medical University of Lodz, Lodz, Poland, 6Biogen Idec Inc., Weston, MA, USA

PND64

QUALITY OF LIFE AND PRODUCTIVITY LOSS IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE) IN SWEDEN; RESULTS FROM A RETROSPECTIVE PATIENT REGISTRY SURVEY IMPLEMENTED BY SWEHA-REG (A POPULATION BASED CENSUS OF HAE IN SWEDEN)

 

Nordenfelt P1, Björkander J1, Mallbris L2, Lindfors A2, Friberg S3, Löfdal K4, Nordvall L5, Werner S6, Wahlgren CF2
1County Hospital Ryhov, Jönköping, Sweden, 2Karolinska University Hospital, Solna, Sweden, 3Heron Evidence Development AB, Stockholm, Sweden, 4Sahlgrenska University Hospital, Gothenburg, Sweden, 5Uppsala Academic Hospital, Uppsala, Sweden, 6University Hospital Lund, Lund, Sweden

NEUROLOGICAL DISORDERS – Health Care Use & Policy Studies

PND65

SPANISH NEUROLOGY THERAPEUTIC SOCIETY GUIDELINES FOR THE TREATMENT OF RELAPSING REMITTING MS: ARE THEY FOLLOWED BY SPANISH NEUROLOGISTS?

 

Balaña M1, Lahoz R2, Río J3, Oreja-Guevara C4, Gobartt A1
1Novartis Farmaceutica, Barcelona, Barcelona, Spain, 2Novartis Farmaceutica, Barcelona, Spain, 3Hospital Universitario Vall d'Hebron, Barcelona, Barcelona, Spain, 4Hospital Clínico San Carlos, Madrid, Madrid, Spain

PND66

THERAPEUTIC EQUIVALENCE AS A MEANS OF IMPROVING THE EFFICIENCY IN THE TREATMENT OF MULTIPLE SCLEROSIS

 

Bautista Paloma FJ1, Flores Moreno S2, Ucles Sanchez A3, Casado Chocan J4, Jimenez Hernandez D5
1Hospital Universitario Virgen del Rocío, Sevilla, Spain, 2Hospital Universitario Virgen del Rocio, Seville, Spain, 3Hospital Virgen del Rocío, seville, Spain, 4Hospital Universitario Virgen del Rocio, seville, Spain, 5Hospital Universitario Virgen del Rocío, Seville, Spain

PND67

THE IMPACT OF MEMANTINE AND CHOLINESTERASE INHIBITORS INITIATION FOR ALZHEIMER'S DISEASE ON THE USE OF ANTIPSYCHOTICS AGENTS: ANALYSIS USING THE RAMQ DATABASE

 

Lachaine J1, Beauchemin C1, Crochard A2, Bineau S2
1University of Montreal, Montreal, QC, Canada, 2Lundbeck S.A.S., Issy-Les-Moulineaux, France

PND68

COMPARISON OF HOSPITALIZATIONS AMONG PARKINSON'S PATIENTS WHO INITIATED THERAPY WITH A DOPAMINE AGONIST OR RASAGILINE: EVIDENCE FROM THE MEDICARE SUPPLEMENTAL DATABASE

 

Grubb E1, Jackson J1, Lage MJ2, Treglia M2
1Teva Pharmaceuticals, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, Delray Beach, FL, USA

PND69

DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED OUTCOMES QUESTIONNAIRE FOR THE ASSESSMENT OF HEREDITARY ANGIOEDEMA IN OBSERVATIONAL STUDIES

 

Bonner N1, Abetz L1, Renault L2, Caballero T3
1Adelphi Values, Bollington, Cheshire, UK, 2Shire HGT, Eysins, Switzerland, 3Hospital Universitario La Paz, Madrid, Spain

PND70

PATIENT CHARACTERISTICS AND TREATMENT STATUS IN PARKINSON'S DISEASE (PD)

 

Grubb E1, Castelli-Haley J1, Treglia M2, Lage MJ2
1Teva Pharmaceuticals, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, Delray Beach, FL, USA

PND71

PREDICTORS OF TREATMENT CLASS CHOICE IN PARKINSON'S DISEASE

 

Grubb E1, Castelli-Haley J1, Treglia M2, Lage MJ2
1Teva Pharmaceuticals, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, Delray Beach, FL, USA

PND72

ACCESS, UPTAKE AND UTILIZATION MANAGEMENT OF MULTIPLE SCLEROSIS PRODUCTS IN THE UNITED STATES

 

Aggarwal S
Novel Health Strategies, Bethesda, MD, USA

PND73

MULTIPLE SCLEROSIS IN GERMANY: OUTPATIENT HEALTH CARE PATTERNS

 

Höer A1, Schiffhorst G1, Fischaleck J2, Gehrmann L2, Ahrens H2, Carl G3, Sigel KO4, Osowski U5, Bleß HH1
1IGES Institut GmbH, Berlin, Germany, 2Kassenärztliche Vereinigung Bayerns, München, Germany, 3Berufsverband Deutscher Nervenärzte BVDN, Kitzingen, Germany, 4Neuropraxis-München Süd, Unterhaching, Germany, 5Merck Serono GmbH, Darmstadt, Germany

PND74

HOW HAVE MANUFACTURERS OVERTURNED NEGATIVE REIMBURSEMENT DECISIONS? A CASE STUDY USING NATALIZUMAB FOR MULTIPLE SCLEROSIS

 

Philips Z, Guarnieri C, Brown A
Abacus International, Manchester, UK

SESSION V – WEDNESDAY, 7 NOVEMBER
SET-UP: Wednesday, 7 November, 8:30-8:45
POSTER DISPLAY HOURS: Wednesday, 7 November, 8:45-14:45
POSTER AUTHOR DISCUSSION HOUR: Wednesday, 7 November, 12:45-13:45
DISMANTLE: Wednesday, 7 November, 14:45

RESPIRATORY-RELATED DISORDERS – Clinical Outcomes Studies

PRS1

THE USE OF MONTELUKAST AND NEUROPSYCHIATRIC DISTURBANCES AMONG PEDIATRIC ASTHMATICS: A NESTED CASE-CONTROL STUDY

 

Ali MM1, O'Brien C1, Cleves M2, Martin B1
1University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA, 2UAMS College of Medicine, Little Rock, AR, USA

PRS2

A RETROSPECTIVE EPIDEMIOLOGIC REVIEW OF COPD IN KOREA

 

Joo H1, Jung KS2, Jeung J1, Lee SH3
1Nycomed Korea Co.,Ltd., Seoul, South Korea, 2Hallym University Sacred Heart Hospital, Gyeonggi-do, South Korea, 3The Catholic University of Korea, Seoul, South Korea

PRS3

REAL WORLD EFFECTIVENESS AND RELATIVE EFFECTIVENESS OF OMALIZUMAB. AN HISTORIC-PROSPECTIVE DESIGN STUDY

 

Grimaldi-Bensouda L1, Abenhaim L2
1LA-SER, Paris, Paris, France, 2LA-SER Europe Ltd., London, London, United Kingdom

PRS4

COMPARATIVE EFFICACY OF ACLIDINIUM BROMIDE 400 MCG BID VERSUS TIOTROPIUM 18 MCG AND 5 MCG QD AS MAINTENANCE BRONCHODILATOR TREATMENT TO RELIEVE SYMPTOMS IN ADULT PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): A NETWORK META-ANALYSIS

 

Karabis A1, Lindner L2, Mocarski M3, Bouwmeester W1, Karakurum C2, Prior M2, Bergman G1
1MAPI Consultancy, Houten, The Netherlands, 2Almirall S.A., Barcelona, Spain, 3Forest Research Institute, Jersey City, NJ, USA

PRS5

DUAL BRONCHODILATION WITH INDACATEROL AND TIOTROPIUM IN COMBINATION VERSUS TRIPLE THERAPY, FIXED-DOSE COMBINATIONS, AND MONOTHERAPY IN COPD – A NETWORK META-ANALYSIS OF FEV1

 

Kraemer M1, Ellis A2, Baldwin M3, Jansen JP2, Capkun-Niggli G1, Cope S2
1Novartis Pharma AG, Basel, Switzerland, 2MAPI Consultancy, Boston, MA, USA, 3Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, UK

PRS6

PREVALENCE OF SELECTED CONDITIONS IN RUSSIA ACROSS SOURCES

 

Vietri J1, Matveev N2, Bhounsule P3, Isherwood G4
1Kantar Health, Princeton, NJ, USA, 2Russian National Research Medical University, Moscow, Russia, 3Kantar Health, New York, NY, USA, 4Kantar Health, Epsom, Surrey, UK

PRS7

PATTERNS OF INTRANASAL CORTICOSTEROID USE AMONG INDIVIDUALS DIAGNOSED WITH ALLERGIC RHINITIS: EVIDENCE FROM A LARGE CLAIMS DATABASE

 

Lage MJ1, Gross GN2, Buck PO3, Lepore MS3
1HealthMetrics Outcomes Research, Delray Beach, FL, USA, 2Dallas Allergy and Asthma Center, Dallas, TX, USA, 3Teva Pharmaceuticals, Frazer, PA, USA

PRS8

BURDEN OF EXACERBATIONS IN PATIENTS WITH COPD IN THE NETHERLANDS: A REAL-LIFE STUDY

 

Overbeek JA1, Balp MM2, Penning FJA1, Dekhuijzen PNR3, Herings RMC1
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Novartis Pharma AG, Basel, Basel, Switzerland, 3Radboud University Medical Centre, Nijmegen, Gelderland, The Netherlands

PRS9

ALLERGIES: DISTRIBUTION AND PERCEPTION IN THE GERMAN GENERAL POPULATION

 

Schaefer I1, Franzke N1, Stadler R2, Augustin M3
1University Clinics of Hamburg UKE, Hamburg, Germany, 2Hautklinik Klinikum, Minden, Germany, 3University Clinics of Hamburg, Hamburg, Germany

PRS10

AN ANALYSIS OF REPORTED PNEUMONIA DEATHS IN MALAYSIA

 

Azmi S, Abdul Aziz SH, Goh A
Azmi Burhani Consulting, Petaling Jaya, Selangor, Malaysia

RESPIRATORY-RELATED DISORDERS – Cost Studies

PRS11

THE SHORT-TERM ECONOMIC IMPACT OF THREE CHILDHOOD PREVENTIVE HEALTH PROGRAMS IN ISRAEL

 

Keller N1, Vo P2, Sambrook R3, Gooch K2, Kendall RM4, Levy AR4
1Sheba Medical Center, Tel Hashomer, Israel, 2Abbott Laboratories, Abbott Park, IL, USA, 3Oxford Outcomes Ltd., Vancouver, BC, Canada, 4Oxford Outcomes, Vancouver, BC, Canada

PRS12

WITHDRAWN

 

 

PRS13

VARIATION OF COST OF CHRONIC OBSTRUCTIVE LUNG DISEASE IN ADULTS IN GERMANY: A SYSTEMATIC REVIEW

 

Kirsch F1, Wenig C1, Menn P2, Leidl R1
1Ludwig-Maximilians-Universität München, Munich, Germany, 2Helmholtz Zentrum München - German Research Center for Environmental Health, Munich, Germany

PRS14

CLINICAL AND PHARMACOECONOMIC ASPECTS OF ALLERGEN IMMUNOTHERAPY IN THE SLOVAK REPUBLIC

 

Bielik J1, Pruzinec P2, Tor P3
1Trencin University, Trencin, Slovak Republic, 2University Hospital, Bratislava, Slovak Republic, 3Stallergenes CZ s.r.o., Bratislava, Slovak Republic

PRS15

THE ECONOMIC IMPACT OF COPD IN PATIENTS OF WORKING AGE: RESULTS FROM ‘COPD UNCOVERED' THE NETHERLANDS

 

van Boven JF1, Van Der Molen T2, Postma MJ3, Vegter S3
1University of Groningen, Groningen, Groningen, The Netherlands, 2University Medical Center Groningen, Groningen, The Netherlands, 3University of Groningen, Groningen, The Netherlands

PRS16

SOCIOECONOMIC BURDEN OF COPD IN UKRAINE: 2012-2020 PERSPECTIVE MODELING

 

Tolubaiev V, Zalis'ka O, Kacheray J
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

PRS17

AVAILABILITY, AFFORDABILITY AND PRICE OF ASTHMA MEDICINES IN TEHRAN; IRAN

 

Kebriaee A1, Rasdidian A2, Ghiasi G2, Salamzadeh J3, Dorkoosh FA2
1Tehran University of Medical Sciences, tehran, Iran, 2TUMS, tehran, Iran, 3Shahid Beheshti University of Medical Sciences, tehran, Iran

PRS18

SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS, UTILITY ESTIMATES, RESOURCE UTILISATION, AND COSTS IN CHRONIC IDIOPATHIC URTICARIA

 

Woods MS1, Zimovetz E1, Beard S1, Balp MM2
1RTI Health Solutions, Manchester, UK, 2Novartis Pharma AG, Basel, Switzerland

PRS19

COST-BENEFIT ANALYSIS OF TIOTROPIUM AND SALMETEROL TREATMENT COMPARE TO USUAL PRACTICE ON SAMPLE OF EMPLOYED ECONOMICALY ACTIVE COPD PATIENTS IN UKRAINE

 

Zalis'ka O1, Tolubaiev V1, Bocharova V2
1Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, 2National Pharmaceutical University, Kharkiv, Ukraine

PRS20

COST-BENEFIT ANALYSIS FOR A TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

 

Iskedjian M1, Walker JH2, McLean A3, Farah B1, Berbari J1, Watson JA4
1PharmIdeas Research and Consulting, Ottawa, ON, Canada, 2Brock University, St Catharines, ON, Canada, 3Unither Biotech Inc., Magog, QC, Canada, 4United Therapeutics Corporation, Research Triangle Park, NC, USA

PRS21

COST-EFFECTIVENESS OF BUDESONIDE/FORMOTEROL VERSUS FLUTICASONE/SALMETEROL BASED ON REAL-WORLD EFFECTIVENESS IN PATIENTS WITH COPD

 

Hedegaard M1, Janson C2, Lisspers K2, Ställberg B2, Johansson G2, Jörgensen L1, Larsson K3
1AstraZeneca, Södertälje, Sweden, 2Uppsala University, BMC, Uppsala, Sweden, 3Karolinska Institutet, Stockholm, Sweden

PRS22

COST-EFFECTIVENESS OF BECLOMETHASONE/FORMOTEROL VERSUS FLUTICASONE/SALMETEROL IN THE TREATMENT OF PATIENT WITH MODERATE TO SEVERE ASTHMA IN SPAIN

 

Collados C1, Ojeda P2, Martín V3, Rejas J4
1Universidad Carlos III de Madrid, Getafe (Madrid), Spain, 2Clínica de Asma y Alergia Dres.
Ojeda, Madrid, Spain, 3Trial Form Support, S.L.,, Alcobendas, Spain, 4Pfizer España, Alcobendas/Madrid, Spain

PRS23

PHARMACOECONOMIC ANALYSIS OF ROFLUMILAST FOR TREATMENT OF ADULT PATIENTS WITH SEVERE-TO-VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

 

Margieva A, Omelyanovsky V, Avxentyeva M, Krysanov I, Zorin N, Andreyeva N
Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia

PRS24

COST-EFFECTIVENESS OF VARENICLINE COMPARED WITH BUPROPION AND NRT (NICORETTE) FOR SMOKING CESSATION IN AUSTRIA

 

Walter E, Mercsanits D
Institute for Pharmaeconomic Research, Vienna, Austria

PRS25

COST ANALYSIS OF OMALIZUMAB USE IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA WITHIN THE MEXICAN PUBLIC HEALTH CARE SYSTEM

 

Lemus-Carmona E1, Reyes-Lopez A2, Jimenez Aranda P3
1Novartis Pharmaceuticals Corporation, Mexico City, Mexico, 2Mexican Children Hospital, Mexico City, Mexico, 3Novartis, Coyoacan, Mexico

PRS26

ECONOMIC EVALUATION OF OMALIZUMAB IN PATIENTS WITH UNCONTROLLED SEVERE ALLERGIC ASTHMA FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

 

Suzuki C1, Pepe C2, Silva NL3
1Novartis, São Paulo, Brazil, 2MedInsight, São Paulo, São Paulo, Brazil, 3Novartis Biociências SA, Sao Paulo, Brazil

PRS27

ONE-YEAR COST-EFFECTIVENESS OF MONTELUKAST IN 2-6-YEAR-OLD CHILDREN WITH MILD-MODERATE PERSISTENT ASTHMA IN BELARUS

 

Kozhanova I1, Romanova I1, Gavrilenko L1, Sachek M2
1Belarusian State Medical University (BSMU), Minsk, Belarus, 2Belarusian Center for Medical Technologies, Minsk, Belarus

PRS28

COST-EFFECTIVENESS ANALYSIS OF MONTELUKAST IN 6-14-YEAR-OLD CHILDREN WITH MILD-MODERATE PERSISTENT ASTHMA IN BELARUS

 

Kozhanova I1, Romanova I1, Gavrilenko L1, Sachek M2
1Belarusian State Medical University (BSMU), Minsk, Belarus, 2Belarusian Center for Medical Technologies, Minsk, Belarus

PRS29

QUEUING STATISTICAL MODEL - A NEW TOOL FOR PRELIMINARY COST-EFFECTIVENESS ASSESSMENTS

 

Kucharczyk P1, Jahnz-Rozyk K2, Kucharczyk A2, Pancer K3
1Military Health Institute of Medicine, Warsaw, Poland, 2Military Institute of Medicine, Warsaw, Poland, 3National Institute of Public Health, Warsaw, Poland

PRS30

COST-EFFECTIVENESS ANALYSIS OF 100% WHEY-BASED PARTIALLY HYDROLYZED INFANT FORMULA USED FOR PREVENTION OF ATOPIC DERMATITIS IN GERMANY

 

Erdogan Ciftci E1, Horodniceanu EG2, Botteman MF3, Detzel P4, Verheggen BG5
1Pharmerit International, Rotterdam, The Netherlands, 2Pharmerit International, Bethesda, MD, USA, 3Pharmerit North America, LLC., Bethesda, MD, USA, 4Nestle Nutrition Institute, VEVEY, Switzerland, 5Pharmerit International, Rotterdam, The Netherlands

PRS31

COST-EFFECTIVENESS OF AN INTENSIVE INTERVENTION PROGRAM IN THE CONTROL OF ALLERGIC RHINITIS DUE TO RAGWEED POLLEN IN QUEBEC, CANADA

 

Lachaine J1, Beauchemin C1, Lapierre ME1, Masson E2, Drapeau JB2, Groulx J2
1University of Montreal, Montreal, QC, Canada, 2Direction de la santé publique, Longueuil, QC, Canada

PRS32

ALLERGY PATIENTS TREATED WITH IMMUNOTHERAPY EXPERIENCE INCREASED QUALITY OF LIFE AND FEWER SICK DAYS AFTER ONE YEAR

 

Petersen KD1, Kronborg C2, Dahl R3, Larsen JN4, Beck SJ5, Gyrd-Hansen D6
1Aalborg University, Aalborg, Denmark, 2University of Southern Denmark, Odense, Denmark, 3Aarhus University, Aarhus, Denmark, 4ALK Abello, Hørsholm, Denmark, 5SKAT (Tax), Odense, Denmark, 6University of Queensland, Brisbane, Australia

RESPIRATORY-RELATED DISORDERS – Patient-Reported Outcomes & Patient Preference Studies

PRS33

FACTORS AFFECTING ADHERENCE TO COPD THERAPY IN 5EU

 

Gross HJ1, Isherwood G2, Vietri J1, Bone O3
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, Epsom, Surrey, UK, 3Kantar Health UK, Epsom, Surrey, UK

PRS34

AUSTRALIAN NEW TO THERAPY PROGRAM IMPROVES TIOTROPIUM (SPIRIVA) PERSISTENCE AND COMPLIANCE

 

Ortiz MS1, Marshall D2, Waterhouse B3, Gallagher R4
1University of NSW, Darlinghurst, NSW, Australia, 2Boehringer Ingelheim Pty Limited, North Ryde, NSW, Australia, 3Model Solutions, Sydney, NSW, Australia, 4GuildLink Pty Ltd, Burwood , NSW, Australia

PRS35

THE ECONOMIC BURDEN OF HAE: FINDINGS FROM THE HAE BURDEN OF ILLNESS STUDY IN EUROPE (HAE-BOIS-EUROPE)

 

Aygören-Pürsün E1, Bygum A2, Caballero T3, Beusterien K4, Hautamaki E4, Musingarimi P5, Wait S6, Boysen H7
1University Hospital, Johann Wolfgang Goethe University, Frankfurt, Germany, 2Odense University Hospital, Odense, Denmark, 3University Hospital La Paz, Madrid, Spain, 4Oxford Outcomes Inc., Bethesda, MD, USA, 5ViroPharma, Maidenhead, UK, 6SHW Health Ltd., London, UK, 7HAEi - International Patient Organization for C1 Inhibitor Deficiencies, Roedekro, Denmark

PRS36

CONTENT VALIDITY OF TWO SYMPTOM QUESTIONNAIRES FOR IDIOPATHIC PULMONARY FIBROSIS

 

Gries KS1, Esser D2, Wiklund I3
1United BioSource Corporation, Seattle, WA, USA, 2Boehringer Ingelheim, Ingelheim, Germany, 3United BioSource Corporation, London, UK

PRS37

QUALITY OF LIFE IN PAEDIATRIC ASTHMA FROM PATIENT AND THEIR PARENTS PERSPECTIVE

 

Meszaros A1, Bodnár R1, Kadar L2
1Semmelweis University, Budapest, Hungary, 2Pest County Pulmonological Institute, Torokbalint, Hungary

PRS38

TURKISH CULTURAL ADAPTATION AND VALIDATION OF SMOKING CESSATION QUALITY OF LIFE (SCQOL) QUESTIONNAIRE

 

Oksuz E1, Malhan S2, Baytar S1, Yilmaz F1
1Baskent University, Ankara, Turkey, 2Baskent University, Anakara, Turkey

PRS39

PREFERENCE AND WILLINGNESS TO PAY FOR A TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

 

Iskedjian M1, Gafni A2, McLean A3, White J4, Provencher S5, Farah B1, Berbari J1, Watson JA6
1PharmIdeas Research and Consulting, Ottawa, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3Unither Biotech Inc., Magog, QC, Canada, 4University of Rochester Medical Center, Rochester, NY, USA, 5Université Laval, Québec, QC, Canada, 6United Therapeutics Corporation, Research Triangle Park, NC, USA

RESPIRATORY-RELATED DISORDERS – Health Care Use & Policy Studies

PRS40

ARE DISEASE MANAGEMENT PROGRAMS FOR COPD COST-SAVING?

 

Boland MRS1, Tsiachristas A1, Kruis A2, Chavannes N2, Rutten-van Mölken MPMH3
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Leiden University, Leiden, Zuid-Holland, The Netherlands, 3Erasmus University, Rotterdam, The Netherlands

PRS41

CHARACTERISTICS AND DETERMINANTS OF PALIVIZUMAB USE IN THE NETHERLANDS

 

Houweling LMA1, Penning-van Beest FJA1, Bezemer ID1, van Lingen RA2, Herings RMC1
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Department of Neonatology Isala Clinics, Zwolle, The Netherlands

PRS42

CURRENT POSITION OF ICS/LABA COMBINATION THERAPY IN ASTHMA AND COPD IN PRIMARY AND SECONDARY CARE IN GERMANYDELPHI CONSENSUS RESEARCH

 

Latif F1, Bechtel B2, Palovis L3, Kardos P4
1Double Helix Consulting, London, UK, 2GlaxoSmithKline GmbH & Co.
KG, Munich, Germany, 3GlaxoSmithKline, Middlesex , UK, 4Gemeinschaftspraxis &. Zentrum für Allergologie, Pneumologie, Schlafmedizin, Frankfurt am Main, Germany

PRS43

BUDGET IMPACT ANALYSIS OF INDACATEROL IN THE TREATMENT OF COPD IN A FINNISH HOSPITAL DISTRICT

 

Agthe N1, Purmonen T1, Kotaniemi J2, Kankaanranta H3
1Oy Medfiles Ltd, Kuopio, Finland, 2Tampere University Hospital, Tampere, Finland, 3Seinäjoki Central Hospital, Seinäjoki, Finland

PRS44

THE IMPACT MADE BY THE CONTINUITY OF CARE FOR COPD PATIENTS ON HEALTH OUTCOMES AND MEDICAL COST IN KOREA, ACCORDING TO THE NATIONAL HEALTH INSURANCE DATABASE

 

Kim Y
National Strategic Coordinating Center for Clinical Research, Seoul, South Korea

PRS45

HEALTH OUTCOMES AND COSTS OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ACCORDING TO THE CONTINUITY OF AMBULATORY CARE WITH KOREAN NATIONAL HEALTH INSURANCE DATABASE

 

Kim Y
National Strategic Coordinating Center for Clinical Research, Seoul, South Korea

PRS46

HEALTH CARE RESOURCE USE OF PATIENTS WITH CYSTIC FIBROSIS (CF) IN THE UNITED KINGDOM

 

Lambrelli D1, Wasiak R1, Ingram A2, Harrow B3, Becker C3, Eriksson D1, Wyatt H4
1United BioSource Corporation, London, UK, 2Xcelerate Health  Outcomes, London, UK, 3Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA, 4King's College Hospital, London, UK

PRS47

ANALYSIS OF NEW PRESCRIPTIONS FOR LONG-ACTING β2-AGONISTS IN FIVE EUROPEAN COUNTRIES IN 2011

 

Price D1, Marshall J2, Turner R2
1University of Aberdeen, Aberdeen, UK, 2Mundipharma International Ltd, Cambridge, UK

SESSION V – WEDNESDAY, 7 NOVEMBER
SET-UP: Wednesday, 7 November, 8:30-8:45
POSTER DISPLAY HOURS: Wednesday, 7 November, 8:45-14:45
POSTER AUTHOR DISCUSSION HOUR: Wednesday, 7 November, 12:45-13:45
DISMANTLE: Wednesday, 7 November, 14:45

SENSORY SYSTEMS DISORDERS – Clinical Outcomes Studies

PSS1

PERSISTENCE WITH STATIN THERAPY AND RISK OF PSORIASIS: A POPULATION-BASED RETROSPECTIVE COHORT STUDY

 

Amital H1, Weitzman D2, Chodick G2, Shalev V2
1Sheba Medical Center, Tel Hashomer, Israel, 2Maccabi Healthcare Services, Tel Aviv, Israel

PSS2

COMPARISONS OF THE CLINICAL EFFECTIVENESS OF TREATMENTS FOR MACULAR OEDEMA (MO) CAUSED BY RETINAL VEIN OCCLUSION (RVO)

 

Edwards SJ1, Barton S1, Trevor N1, Lois N2, Nherera L1, Hamilton V1
1BMJ Group, London, UK, 2Aberdeen Royal Infirmary, Aberdeen, UK

PSS3

THE EFFICACY OF EPIDERMAL GROWTH FACTOR IN BURN WOUND TREATMENT

 

Namviriyachote N1, Aramwit P1, Muangman P2
1Chulalongkorn University, Bangkok, Thailand, 2Mahidol University, Bangkok, Thailand

PSS4

ACNE AND LIFESTYLE: RESULTS OF A SURVEY ON A REPRESENTATIVE SAMPLE OF THE FRENCH POPULATION

 

Wolkenstein P1, Misery L2, Amici JM3, Maghia R4, Cazeau C5, Voisard JJ5, Taieb C6
1Creteil Hospital, Creteil, France, 2Brest Hospital, Brest, France, 3Hôpital Saint André, Bordeaux, France, 4Dermatology, Brives, France, 5PFD, Lavaur, France, 6CREES PFSA, Boulogne , France

SENSORY SYSTEMS DISORDERS – Cost Studies

PSS5

BEVACIZUMAB VERSUS RANIBIZUMAB FOR AGE-RELATED MACULAR DEGENERATION (AMD): A BUDGET IMPACT ANALYSIS

 

Zimmermann I, Schneiders RE, Mosca M, Alexandre RF, do Nascimento Jr JM, Gadelha CA
Ministry of Health, Brasília, DF, Brazil

PSS6

COST-OF-ILLNESS OF CHRONIC LYMPHOEDEMA PATIENTS IN HAMBURG AND SUBURBAN REGION

 

Purwins S1, Dietz D1, Blome C2, Heyer K1, Herberger K1, Augustin M1
1University Clinics of Hamburg, Hamburg, Germany, 2University Medical Center Hamburg, Hamburg, Germany

PSS7

C-REALITY (CANADIAN BURDEN OF DIABETIC MACULAR EDEMA OBSERVATIONAL STUDY): 6-MONTH FINDINGS

 

Barbeau M1, Gonder J2, Walker V3, Zaour N1, Hartje J4, Li R1
1Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2St. Joseph's Health Care, London, ON, Canada, 3OptumInsight, Burlington, ON, Canada, 4OptumInsight, Eden Prairie, MN, USA

PSS8

NON-INTERVENTIONAL STUDY ON THE BURDEN OF ILLNESS IN DIABETIC MACULAR EDEMA (DME) IN BELGIUM

 

Nivelle E1, Caekelbergh K1, Moeremans K1, Gerlier L2, Drieskens S3, Van Dijck P4
1IMS Health HEOR, Vilvoorde, Belgium, 2IMS Health, Vilvoorde, Belgium, 3Panacea Officinalis, Antwerp, Belgium, 4N.V. Novartis Pharma S.A., Vilvoorde, Belgium

PSS9

COST OF BLINDNESS AND VISUAL IMPAIRMENT IN SLOVAKIA

 

Psenkova M1, Mackovicova S2, Ondrusova M3, Szilagyiova P4
1Pharm-In, Bratislava, Slovak Republic, 2Pharm-In, spol. s r.o., Bratislava, Slovak Republic, 3Pharm-In, Ltd., Bratislava, Slovak Republic, 4Pfizer Luxembourg SARL, Bratislava, Slovak Republic

PSS10

ECONOMICAL BURDEN OF SEVERE VISUAL IMPAIRMENT AND BLINDNESS – A SYSTEMATIC REVIEW

 

Köberlein J1, Beifus K1, Finger R2
1University of Wuppertal, Wuppertal, Germany, 2University of Bonn, Bonn, Germany

PSS11

ECONOMIC EVALUATION OF BIOLOGIC TREATMENTS FOR MODERATE TO SEVERE PSORIASIS IN ITALY

 

Marcellusi A1, Gitto L1, Giannantoni P1, Attinà G2, Sundaram M3, Mennini FS1
1University of Rome, Rome, Italy, 2Abbott Italy, Latina, Italy, 3QualityMetric Health Outcomes Solutions, Lincoln, RI, USA

PSS12

NEPAFENAC FOR THE REDUCTION IN RISK OF POST-OPERATIVE MACULAR OEDEMA ASSOCIATED WITH CATARACT SURGERY IN DIABETIC PATIENTS: A COST-EFFECTIVENESS ESTIMATION FOR SCOTLAND

 

Jackson D1, Fisher R2, Latif F3
1Alcon Laboratories, Hünenberg, Switzerland, 2Alcon Laboratories, Camberley, UK, 3Double Helix Consulting, London, UK

PSS13

COST-EFFECTIVENESS OF SPECIALIZED TREATMENT BASED ON COGNITIVE BEHAVIOURAL THERAPY VERSUS USUAL CARE FOR TINNITUS

 

Maes IH1, Cima RF2, Anteunis LJ1, Baguley DM3, El Refaie A4, Scheijen DJ5, Vlaeyen JJ6, Joore MA7
1Maastricht University Medical Centre, Maastricht, The Netherlands, 2Maastricht University, Maastricht, The Netherlands, 3University of Cambridge, Cambridge, UK, 4University of Bristol, Bristol, UK, 5Adelante Audiologie & Communicatie, Hoensbroek, The Netherlands, 6University of Leuve, Leuven, Belgium, 7MUMC, Maastricht, The Netherlands

PSS14

COST-EFFECTIVENESS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GERMANY

 

Betts K1, Yan Y2, Sundaram M3, Hengst N4, Wolff M4, Bensimon AG1
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Inc., New York, NY, USA, 3Abbott Laboratories, Abbott Park, IL, USA, 4Abbott GmbH & Co. KG, Ludwigshafen, Germany

PSS15

A NEW INSIGHT INTO COST-EFFECTIVENESS ANALYSES IN ATOPIC DERMATITIS: THE TACROLIMUS 0.1% OINTMENT VERSUS CICLOSPORIN COMPARISON

 

Almeida J1, Vandewalle B1, Silva MJ2, Félix J1
1Exigo Consultores, Alhos Vedros, Setúbal, Portugal, 2Exigo Consultores, Alhos Vedros, Lisbon, Portugal

PSS16

COST-EFFECTIVENESS OF TACROLIMUS OINTMENT IN CHILDREN WITH MODERATE AND SEVERE ATOPIC DERMATITIS: TWICE-DAILY MAINTENANCE TREATMENT VERSUS STANDARD TWICE-DAILY REACTIVE TREATMENT OF EXACERBATIONS FROM THE PERSPECTIVE OF THE SPANISH NATIONAL HEALTH SERVICE

 

Munro V1, Hart WM2
1Astellas Pharma Europe Ltd., Staines, Middlesex, UK, 2EcoStat Consulting Ltd, Sidestrand, Norfolk, UK

PSS17

CLINICAL AND ECONOMIC ANALYSIS OF LINEZOLID FOR THE TREATMENT OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS CONFIRMED COMPLICATED SKIN AND SOFT TISSUE INFECTIONS UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM

 

Fujii RK1, Pepe C2, Mould JF3, Lanzara G4, Sales LH5
1Pfizer, Inc., São Paulo, São Paulo, Brazil, 2MedInsight, São Paulo, São Paulo, Brazil, 3Pfizer, New York, NY, USA, 4Pfizer Pharmaceuticals, Inc., São Paulo, São Paulo, Brazil, 5Medinsight – Decisions in Health Care, São Paulo, Brazil

PSS18

RANIBIZUMAB FOR THE TREATMENT OF MACULAR EDEMA DUE TO RETINAL VEIN OCCLUSION (RVO) IN THE UK: A COST-UTILITY ANALYSIS

 

Taylor M1, Serbetci E1, Ferreira A2, Gairy K3, Blouin J4, Mitchell P5, Lewis L1
1University of York, York, UK, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharmaceuticals UK Limited, Frimley, UK, 4Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 5University of Sydney, Australia, Westmead, Australia

PSS19

ECONOMIC EVALUATION OF RANIBIZUMAB FOR THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH AND CENTRAL RETINAL VEIN OCCLUSION IN CANADA

 

Haig J1, Lawrence D1, Barbeau M2, Blouin J2, Zaour N2
1OptumInsight, Burlington, ON, Canada, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

PSS20

COST-UTILITY ANALYSIS OF TREATMENTS FOR MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION

 

Duff S1, Gricar J2, Kymes S3, Tran I4, Turpcu A5, Sternberg G5
1Veritas Health Economics Consulting, Carlsbad, CA, USA, 2Apo-Med, New York, NY, USA, 3Washington University School of Medicine, St. Louis, MO, USA, 4Roche Pharmaceuticals, Welwyn Garden City, United Kingdom, 5Genentech, South San Francisco, CA, USA

SENSORY SYSTEMS DISORDERS – Patient-Reported Outcomes & Patient Preference Studies

PSS21

EVALUATION OF HEALTH UTILITY IN PATIENTS WITH RETINAL VEIN OCCLUSION

 

Balshaw RF1, Gonder J2, Ferreira A3, Zaour N4, Blouin J4, Barbeau M4
1Syreon Corp, Vancouver, BC, Canada, 2St. Joseph's Health Care, London, ON, Canada, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

PSS22

IMPACT OF PATIENT SATISFACTION ON HEALTH RELATED QUALITY OF LIFE, IN PSORIASIS PATIENTS RECEIVING TRADITIONAL SYSTEMIC THERAPY

 

O'Hara J1, Broomfield S1, Thompson G2, Piercy J1
1Adelphi Real World, Bollington, UK, 2Janssen-Cilag Ltd., High Wycombe, UK

PSS23

PATIENT BURDEN ASSOCIATED WITH LACK OF TREATMENT SATISFACTION AMONGST PSORIASIS PATIENTS RECEIVING TRADITIONAL SYSTEMIC THERAPIES

 

O'Hara J1, Lobosco S1, Thompson G2, Piercy J1
1Adelphi Real World, Bollington, UK, 2Janssen-Cilag Ltd., High Wycombe, UK

PSS24

HOW DO GLAUCOMA PATIENTS ASSESS DIFFERENT ASPECTS OF THEIR TREATMENT: AN ELICITATION OF PATIENTS' PREFERENCES USING THE ANALYTIC HIERARCHY PROCESS

 

Dintsios CM1, Scheibler FF2, Janssen I2, Gerber A3, Chernyak N4, Finger R5
1German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany, 2IQWiG, Cologne, Germany, 3Institute of Quality and Efficiency in Health Care (IQWiG), Köln, Germany, 4Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, 5University of Bonn, Bonn, Germany

PSS25

VALIDATION OF THE PATIENT BENEFIT INDEX (PBI) FOR THE ASSESSMENT OF PATIENT-DEFINED BENEFIT IN THE TREATMENT OF PSORIASIS

 

Feuerhahn J1, Blome C2, Radtke MA1, Augustin M1
1University Clinics of Hamburg, Hamburg, Germany, 2University Medical Center Hamburg, Hamburg, Germany

PSS26

NAIL ASSESSMENT IN PSORIASIS AND PSORIATIC ARTHRITIS (NAPPA): AN INTEGRATED APPROACH OF OUTCOMES MEASUREMENT IN NAIL PSORIASIS

 

Augustin M1, Blome C2, Costanzo A3, Dauden E4, Ferrandiz C5, Girolomoni G6, Gniadecki R7, Iversen L8, Menter A9, Michaelis-Wittern K10, Morita A11, Nakagawa H12, Reich K13
1University Clinics of Hamburg, Hamburg, Germany, 2University Medical Center Hamburg, Hamburg, Germany, 3University of Rome, Roma, Italy, 4Hospital Universitario La Princesa, Madrid, Spain, 5Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain, 6University of Verona, Verona, Italy, 7University of Copenhagen, Copenhagen, Denmark, 8Department of Dermatology, Aarhus, Denmark, 9Baylor Research Institute, Dallas, TX, USA, 10SCIderm GmbH, Hamburg, Germany, 11Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan, 12The Jikei University, School of Medicine, Tokyo, Japan, 13Dermatologikum Hamburg, Hamburg, Germany

PSS27

DO SCARS IMPACT BEYOND JUST APPEARANCE? A REPORT OF THE CONTENT ELICITATION (CE) PHASE IN THE DEVELOPMENT OF THE PATIENT REPORTED SCAR EVALUATION QUESIONNAIRE (PR-SEQ)

 

Pleil A1, Jensen J1, Galipeau N2, Olude O2, Klemm M2, Shields A2
1Pfizer, Inc., San Diego, CA, USA, 2Adelphi Values, Boston, MA, USA

PSS28

LONG-TERM IMPROVEMENT IN PATIENT-REPORTED OUTCOMES AFTER TRANSITION FROM METHOTREXATE TO USTEKINUMAB IN MODERATE TO SEVERE PSORIASIS: TRANSIT WEEK 52 RESULTS

 

Reich K1, Puig L2, Luger T3, Lambert J4, Chimenti S5, Girolomoni G6, Nicolas JF7, Kragballe K8, Mistry S9, Bergmans P10, Thompson G9, Barker J11, Paul C12
1Georg-August University, Hamburg, Germany, 2Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, 3University of Münster, Münster, Germany, 4Ghent University Hospital, Ghent, Belgium, 5University of Rome, Rome, Italy, 6University of Verona, Verona, Italy, 7University of Lyon, Lyon, France, 8Århus University, Århus, Denmark, 9Janssen-Cilag Ltd., High Wycombe, UK, 10Janssen-Cilag BV, Tilburg, The Netherlands, 11St John's Institute of Dermatology, King's College, London, UK, 12Larrey Hospital, Paul Sabatier University, Toulouse, France

PSS29

ASSESSING THE CLINICAL MEANINGFULNESS OF 1-LINE AVERAGE CHANGE IN VISUAL ACUITY AMONG PATIENTS WITH DIABETIC MACULAR EDEMA: EVIDENCE FROM HEALTH-RELATED QUALITY OF LIFE CHANGES

 

Liu Y, Liu CC, Campbell J, Li XY, Hashad Y, Kowalski JW
Allergan, Inc., Irvine, CA, USA

PSS30

COSMECEUTIQOL: A DERMO-COSMETIC QUALITY-OF-LIFE ASSESSMENT TOOL

 

Taieb C1, Perez-Cullell N2, Branchoux S3
1CREES PFSA, Boulogne , France, 2Eau Thermale Avene, Lavaur, France, 3Pierre Fabre, Boulogne Billancourt, France

SENSORY SYSTEMS DISORDERS – Health Care Use & Policy Studies

PSS31

PREVALENCE OF CHRONIC WOUNDS IN GERMANY — A SECONDARY DATA ANALYSIS

 

Spehr C1, Schäfer I1, Kornek T1, Siebert J1, Augustin M2
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2University Clinics of Hamburg, Hamburg, Germany

PSS32

PREDICTORS OF BIOLOGIC TREATMENT IN PSORIASIS POPULATION

 

Fan T1, Smith N1, Puig L2, Sen S1
1Merck & Co. Inc., Whitehouse Station, NJ, USA, 2Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

PSS33

TREATMENT PATTERNS OF BIOLOGIC USE IN PSORIASIS PATIENTS IN ENGLAND

 

Khalid JM1, Fox KM2, Globe G3, Maguire A1, Chau D3
1United BioSource Corporation, London, UK, 2Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 3Amgen Inc., Thousand Oaks, CA, USA

PSS34

IMPACT OF SPECIALTY ON PATIENT-PHYSICIAN INTERACTION AND TREATMENT PATTERNS: AN ON-LINE STUDY OF ECZEMA PATIENTS

 

Cascade E1, Burgess AJ2, Gee B3, Downing J4, Nixon M2
1Quintiles, Rockville, MD, USA, 2Quintiles/Outcome, Reading, Berkshire, UK, 3Warwick Hospital, Warwick, UK, 4Quintiles, Durham, North Carolina, USA

PSS35

FREQUENCY OF RANIBIZUMAB INJECTIONS FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION: CANADIAN REAL-WORLD UTILIZATION DATA

 

Davies B1, Gonder J2, Blouin J1, Zaour N1
1Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2St. Joseph's Health Care, London, ON, Canada



15th Annual European Congress Index Page